



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/771,774	02/04/2004	Hubert Barth	PC20545A	4105

7590

09/20/2006

Craig Bell
Pfizer, Inc
150 East 42nd Street
New York, NY 10017-5755

EXAMINER

TRUONG, TAMTHOM NGO

ART UNIT

PAPER NUMBER

1624

DATE MAILED: 09/20/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary
for Applications
Under Accelerated Examination**

Application No.

10/771,774

Applicant(s)

BARTH ET AL.

Examiner

Tamthom N. Truong

Art Unit

1624

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Since this application has been granted special status under the accelerated examination program,
NO extensions of time under 37 CFR 1.136(a) will be permitted and a SHORTENED STATUTORY PERIOD FOR
REPLY IS SET TO EXPIRE:**

**ONE MONTH OR THIRTY (30) DAYS, WHICHEVER IS LONGER,
FROM THE MAILING DATE OF THIS COMMUNICATION -- if this is a non-final action or a Quayle action.
(Examiner: For FINAL actions, please use PTOL-326.)**

The objective of the accelerated examination program is to complete the examination of an application within twelve months from the filing date of the application. Any reply must be filed electronically via EFS-Web so that the papers will be expeditiously processed and considered. If the reply is not filed electronically via EFS-Web, the final disposition of the application may occur later than twelve months from the filing of the application.

Status

- 1) ☒ Responsive to communication(s) filed on 5-30-06 (Election).
2) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 3) ☒ Claim(s) 1-55 is/are pending in the application.
3a) Of the above claim(s) 12-55 is/are withdrawn from consideration.
4) ☐ Claim(s) _____ is/are allowed.
5) ☒ Claim(s) 1,2 and 7-11 is/are rejected.
6) ☒ Claim(s) 3-6 is/are objected to.
7) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 8) ☐ The specification is objected to by the Examiner.
9) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
10) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 11) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☒ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date 8-14-06.
4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.
5) ☐ Notice of Informal Patent Application
6) ☐ Other: _____.

DETAILED ACTION

Applicant's election with traverse of Group 1 (claims 1-11) in the reply filed on 5-30-06 is acknowledged. The traversal is on the ground(s) that "prosecution of the restricted subject matter in one application would not place a serious burden on the Examiner." This is not found persuasive for the following reasons:

- a. Groups I-VI are drawn to different processes of making compounds of different formulae. Although the quinazoline is the common core, each formula has different side chain which makes it distinct from others and requires a **separate search**. Also, each process has different sequential steps which demand more attention in determining relevancy of prior arts.
- b. Groups VII and VIII are drawn to compounds of formulae 49 and 45 which are intermediates, and might have different uses.
- c. It is maintained that the search and examination of 8 groups (or 55 claims) imposes serious burden on the examiner.

The requirement is still deemed proper and is therefore made FINAL.

Claims 1-11 are considered.

Claims 12-55 are withdrawn as being drawn to the non-elected subject matter.

Claim Objections

1. **Improper Multiple Dependent Claims:** Claims 3-6 are objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim must refer to

preceding claims in the alternative language. See MPEP § 608.01(n). Accordingly, the claims 3-6 have not been further treated on the merits.

Claim Rejections - 35 USC § 112, Second Paragraph

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

2. Claims 1, 2 and 7-10 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 1 and dependents thereon are rejected for reciting the limitation of “ester, amide or prodrug thereof” which has indefinite metes and bounds. It is unclear where the site is for the ester, amide or prodrug. Also, many substituents are in ester or amide form which makes it unclear if an additional ester or amide is intended by the claim.

Claim Rejections - 35 USC § 112, First Paragraph

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

3. **Lack Written Description:** Claims 1, 2 and 7-10 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Claim 1 recites the step of converting the compound of formula I to a pharmaceutically acceptable ester, amide or prodrug thereof. However, the specification does not describe a possible ester, amide or prodrug. It also does not provide starting materials or reaction conditions for such a conversion. The specification only lists references for a description of prodrugs; however, such said references are not sufficient to support a process of making an ester, amide or a prodrug of the particularly claimed quinazoline.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

4. Claims 1, 2 and 7-11 are rejected under 35 U.S.C. 103(a) as being unpatentable over

Small et. al. (J. Med. Chem. 2000, Vol. 43, pp. 1380-1397) in view of **Himmelsbach et. al.** (US

6,627,634 B2). On page 1381, Scheme 2 describes a general process of making compound #18 (which is the same compound recited in the instant claim 11). Page 1390 details the process of making such a compound. Note, the term "comprising" in claim 1 does not exclude any steps leading up to formula 10.

The disclosed process differs from the claimed process by not having a G (or protecting) group on the amino (of the anilino). However, such a difference can be overcome by the teaching of Himmelsbach et. al. On columns 10-13, Himmelsbach et. al. describe a generic process of making a quinazoline compound with analogous substituents at the 4th, 6th and 7th positions. Then, on column 13, Himmelsbach et. al. discuss the possibility of having a protecting group on the amino, see the following excerpt:

In the reactions described hereinbefore, any reactive groups present such as hydroxy, carboxy, amino, alkylamino, or imino groups may be protected during the reaction by conventional protecting groups which are cleaved again after the reaction.

For example, a protecting group for a hydroxy group may be a trimethylsilyl, acetyl, benzoyl, methyl, ethyl, tert-butyl, trityl, benzyl, or tetrahydropyranyl group,

protecting groups for a carboxy group may be a trimethylsilyl, methyl, ethyl, tert-butyl, benzyl, or tetrahydropyranyl group, and

protecting groups for an amino, alkylamino, or imino group may be a formyl, acetyl, trifluoroacetyl, ethoxycarbonyl, tert-butoxycarbonyl, benzyloxycarbonyl, benzyl, methoxy-benzyl, or 2,4-dimethoxybenzyl group and additionally, for the amino group, a phthalyl group.

Any protecting group used is optionally subsequently cleaved for example by hydrolysis in an aqueous solvent, e.g., in water, isopropanol/water, acetic acid/water, tetrahydrofuran/water, or dioxane/water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid, or sulfuric acid, or in the presence of an alkali metal base such as sodium hydroxide or potassium hydroxide, or aprotically, e.g., in the presence of iodotrimethylsilane, at temperatures between 0° C. and 120° C., preferably at temperatures between 10° C. and 100° C.

Note, not only Himmelsbach et. al. disclosing several protecting groups for an amino, but they also reveal reagents or reaction conditions to cleave such a group.

Thus, with the teaching of Himmelsbach et. al., the skilled chemist would have been motivated to modify the process of Small et. al. by having a protecting group on the amino (of the anilino).


Therefore, at the time that the invention was made, it would have been obvious to make a compound of formula I by combining the two teachings above.

No pending claim is allowed.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tamthom N. Truong whose telephone number is 571-272-0676. The examiner can normally be reached on M, T and Th (9:00-5:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.


Tamthom N. Truong
Examiner
Art Unit 1624

9-14-06


JAMES O. WILSON
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

[illegible]

Notice of References Cited	Application/Control No. 10/771,774	Applicant(s)/Patent Under Reexamination BARTH ET AL.	
	Examiner Tamthom N. Truong	Art Unit 1624	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	A	US-6,627,634	09-2003	Himmelsbach et al.	514/266.22
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	SMALL J.B. et. al., "Tyrosine Kinase Inhibitors..." J. Med. Chem., 2000, Vol. 43, No. 7, pp. 1380-97.
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

[Handwritten Signature]

9/14/06

Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-*d*]pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions

Jeff B. Smaill,[†] Gordon W. Rewcastle,[†] Joseph A. Loo,[†] Kenneth D. Greis,[§] O. Helen Chan,[‡] Eric L. Reyner,[‡] Elke Lipka,[†] H. D. Hollis Showalter,[‡] Patrick W. Vincent,[†] William L. Elliott,[†] and William A. Denny^{*,†}

Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland, New Zealand, and Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, 2800 Plymouth Road, Ann Arbor, Michigan 48106-1047


Received September 21, 1999

4-Anilinoquinazoline- and 4-anilinopyrido[3,2-*d*]pyrimidine-6-acrylamides substituted with solubilizing 7-alkylamine or 7-alkoxyamine side chains were prepared by reaction of the corresponding 6-amines with acrylic acid or acrylic acid anhydrides. In the pyrido[3,2-*d*]pyrimidine series, the intermediate 6-amino-7-alkylamines were prepared from 7-bromo-6-fluoropyrido[3,2-*d*]pyrimidine via Stille coupling with the appropriate stannane under palladium-(0) catalysis. This proved a versatile method for the introduction of cationic solubilizing side chains. The compounds were evaluated for their inhibition of phosphorylation of the isolated EGFR enzyme and for inhibition of EGF-stimulated autophosphorylation of EGFR in A431 cells and of heregulin-stimulated autophosphorylation of *erbB2* in MDA-MB 453 cells. Quinazoline analogues with 7-alkoxyamine solubilizing groups were potent irreversible inhibitors of the isolated EGFR enzyme, with $IC_{50[app]}$ values from 2 to 4 nM, and potently inhibited both EGFR and *erbB2* autophosphorylation in cells. 7-Alkylamino- and 7-alkoxyaminopyrido[3,2-*d*]pyrimidines were also irreversible inhibitors with equal or superior potency against the isolated enzyme but were less effective in the cellular autophosphorylation assays. Both quinazoline- and pyrido[3,2-*d*]pyrimidine-6-acrylamides bound at the ATP site alkylating cysteine 773, as shown by electrospray ionization mass spectrometry, and had similar rates of absorptive and secretory transport in Caco-2 cells. A comparison of two 7-propoxymorpholide analogues showed that the pyrido[3,2-*d*]pyrimidine-6-acrylamide had greater amide instability and higher acrylamide reactivity, being converted to glutathione adducts in cells more rapidly than the corresponding quinazoline. This difference may contribute to the observed lower cellular potency of the pyrido[3,2-*d*]pyrimidine-6-acrylamides. Selected compounds showed high *in vivo* activity against A431 xenografts on oral dosing, with the quinazolines being superior to the pyrido[3,2-*d*]pyrimidines. Overall, the quinazolines proved superior to previous analogues in terms of aqueous solubility, potency, and *in vivo* antitumor activity, and one example (CI 1033) has been selected for clinical evaluation.

Introduction

Overexpression of the epidermal growth factor receptor (EGFR) tyrosine kinase is associated with poor prognosis in a significant proportion of human tumors.^{1,2} Compounds that inhibit EGFR autophosphorylation and concomitantly EGF-stimulated signal transduction are potentially a new class of anticancer drugs.^{3–5} The most potent and selective EGFR inhibitors reported to date are the 4-anilinoquinazolines and related 4-anilinopyrido[3,2-*d*]pyrimidines.^{6–10} These compounds bind reversibly at the ATP binding domain of EGFR, and two examples (1, 2) are reported to be in clinical trial.^{11,12}

In a further development of this class, we have recently reported^{13,14} that acrylamide-substituted 4-anilinoquinazolines and 4-anilinopyrido[3,2-*d*]pyrimidines (e.g.



3, 4) are potent, selective, and irreversible inhibitors of the *erbB* family of receptor tyrosine kinases. These compounds also bind in the ATP domain of the EGFR but then alkylate the enzyme at cysteine 773, irreversibly shutting down EGFR autophosphorylation.¹³ They show superior *in vivo* activity in animal tumor models in comparison with related reversible inhibitors, par-

* To whom correspondence should be addressed. Tel: 64 9 3737 599, ext. 6144. Fax: 64 9 3737 502. E-mail: b.denny@auckland.ac.nz.

[†] The University of Auckland.

[‡] Parke-Davis Pharmaceutical Research.

[§] Current address: Procter & Gamble Pharmaceuticals, 8700 Mason-Montgomery Rd., Mason, OH 45040.

ticularly by oral dosing regimens.¹⁴ Structure–activity and molecular modeling studies have shown that positioning of the acrylamide at the 6-position is optimal for rapid irreversible inhibition (appropriate positioning of the Michael acceptor with respect to the cysteine SH).¹³ Apart from this requirement, wide variation in the drug structure is tolerated, with 6-acrylamide-substituted 4-anilinoquinazolines, 4-anilino-6-acrylamide-substituted 4-anilinoquinazolines, 4-anilino-6-acrylamide-substituted 4-anilinoquinazolines, 4-anilino-6-acrylamide-substituted 4-anilinoquinazolines, 4-anilino-6-acrylamide-substituted 4-anilinoquinazolines all being potent, selective, irreversible inhibitors of EGFR autophosphorylation.^{13,14}

As part of further investigations of structure–activity relationships in this new series of irreversible EGFR inhibitors, we now report the synthesis and biological activity of a series of quinazoline-6-acrylamides (compounds 5–19) and pyrido[3,2-*d*]pyrimidine-6-acrylamides (compounds 20–27) substituted with solubilizing cationic side chains at positions separate from the Michael acceptor. We show that the 7-substituted compounds are superior in terms of aqueous solubility, potency, and in vivo antitumor activity to previous analogues. One example (18, PD 183805) has been selected for clinical evaluation (as the dihydrochloride salt, CI 1033).¹⁵


Chemistry

The acrylamides (5–11, 13, 14, 16, 18, 19, 21–27) of Table 1 were obtained by direct coupling of their precursor amines (37, 38, 47a–e, 48a,b, 49b, 50b,f, 61, 63, 72a–c, 75, 72d, respectively) with acrylic acid. In general 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI·HCl) was employed as the coupling reagent. However acylation of amine 50f was achieved using the mixed anhydride from acrylic acid and isobutyl chloroformate. EDCI-promoted acylation of the 6-aminopyrido[3,2-*d*]pyrimidine nucleus was exceedingly slow due to low nucleophilicity of the amines, and therefore the reactive mixed anhydride formed from acrylic acid and 2,4,6-trichlorobenzoyl chloride was employed.

The 6-aminoquinazolines 37 and 38 required first the synthesis of anilines 30 and 33 (Scheme 1). 2-Bromo-4-nitrobenzyl bromide (28)¹⁶ was reacted with dimethylamine to give benzylamine 29, which was subsequently reduced with iron dust to aniline 30. Alkylation of 2-bromo-4-nitrophenol (31) with 2-dimethylaminoethyl chloride hydrochloride gave nitrobenzene 32, which was reduced to aniline 33 by iron dust in low yield, whereas hydrogenation over Pt–C gave aniline 33 in acceptable yield (56%). Reaction of anilines 30 and 33 with 4-chloro-6-nitroquinazoline (34)¹⁷ gave the 6-nitroquinazolines 35 and 36, respectively, which underwent subsequent iron dust reduction to give the desired 6-aminoquinazolines 37 and 38.


The 6-amino-7-alkoxyquinazolines (47a–d, 48a,b, 49b, 50b,f) and the 6-amino-7-thioalkoxyquinazoline (47e) were each obtained from their 7-fluoro-6-nitroquinazoline precursors (39–42) by displacement of the activated fluorine with the sodium (or potassium) alkoxide (or sodium thioalkoxide) of the requisite amine side chain (Scheme 2). The sodium alkoxide was generated by reaction of the alcohol with either sodium metal or sodium hydride in THF, the latter giving a more efficient conversion and therefore better control of the

Scheme 1^a



^a (i) MeOH/Me₂NH/20 °C/1 h; (ii) Cl(CH₂)₂NMe₂·HCl/K₂CO₃/DMF/100 °C/4 h; (iii) Fe/AcOH/EtOH/H₂O/reflux/20 min or H₂/Pt–C (for 32); (iv) *i*-PrOH/CH₂Cl₂/Et₃N/reflux/3 h; (v) CH₂=CHCO₂H/EDCI·HCl/pyridine/DMA/20 °C/2 h.


Scheme 2^a



^a (i) RO[−]Na⁺/THF/reflux/18–24 h or RS[−]Na⁺/DMSO/65 °C (for 39–43e) or RO[−]K⁺/DMSO/25 °C (for 42–46f); (ii) Fe/AcOH/EtOH/H₂O/reflux/20 min or H₂/Pd–C/MeOH/EtOAc (2:1) (for X = 3'-Me) or H₂/Raney Ni/THF (for 46f); (iii) CH₂=CHCO₂H/EDCI·HCl/pyridine or Et₃N/DMA or DMF/2 h or (for 50f) CH₂=CHCO₂H/*i*-BuOCOC/Cl/Et₃N/THF.


number of equivalents of alkoxide employed. At least 2 equiv of alkoxide are required, with the first equivalent deprotonating the 4-anilino proton to give a characteristic dark red/purple anion in solution. However, when excess alkoxide was used in the reaction of 39 to give 43c the only product isolated was the amine 47c (in low yield), a result of alkoxide displacement and subsequent in situ nitro group reduction. Iron dust reduction of the 6-nitroquinazolines 43a,b,d,e, 45b, and 46b gave the 6-aminoquinazolines 47a,b,d,e, 49b, and 50b, respectively in excellent yield, while catalytic hydrogenation of the 6-nitroquinazolines 44a,b,f gave the required 6-aminoquinazolines 48a,b and 50f, respectively, also in excellent yield.

The 6-aminopyrido[3,2-*d*]pyrimidines 61 and 63 were both obtained from the key intermediate 7-bromo-6-

Scheme 3^a

fluoropyrido[3,2-*d*]pyrimidine (57) (Scheme 3). This intermediate is synthesized in good overall yield from chloropyridine 51.⁹ Initial reaction with ammonia introduces the amino functionality at the 2-position of pyridine 52, which was required for the activation and directing of subsequent bromination at the adjacent 3-position, to give the bromopyridine 53. Iron dust reduction of 53 gave diamine 54 which was converted to the pyrido[3,2-*d*]pyrimidone 55 in refluxing triethyl orthoformate. At this stage the 6-amino group of 55 is essentially "protected" by diazotization to fluorine, to give the 6-bromo-7-fluoropyrido[3,2-*d*]pyrimidone (56) (at a later stage this activated fluorine is readily displaced by ammonia to regenerate the required amine functionality at this position). Chlorination of the pyrimidone 56 in POCl_3 and displacement with 3-chloro-4-fluoroaniline gave the required intermediate 7-bromo-6-fluoropyrido[3,2-*d*]pyrimidine (57).

Model studies showed that Stille coupling of 57 with tetra vinyltin and allyltributylstannane gave the respective 7-vinyl and 7-allyl derivatives of 57 in good yield (data not shown), with the expected complete selectivity for bromine over chlorine and fluorine. Therefore it was decided to introduce the required alkylmorpholine side chain via Stille coupling of the morpholinostannane 59. Stannane 59 was synthesized in good yield from 3-butyne-1-ol by mesylation and displacement with morpholine to give butyne (58) which underwent AIBN-initiated radical hydrostannylation with tributyltin hydride to give predominantly the *E*-stannane 59 which could be further purified by chromatography. Stille coupling of


Scheme 4^a

(i) CuCN/NMP ; (ii) $90\% \text{H}_2\text{SO}_4$; (iii) $\text{H}_2/\text{Pd}-\text{C}$; (iv) $(\text{EtO})_3\text{CH}/\text{reflux}/8\text{ h}$; (v) $\text{Fe}/\text{AcOH}/\text{EtOH}/\text{H}_2\text{O}/\text{reflux}/20\text{ min}$; (vi) $\text{HCO}_2\text{H}/\text{H}_2\text{SO}_4/\text{reflux}/16\text{ h}$; (vii) POCl_3 , then ArNH_2 ; (viii) *m*-CPBA/ $\text{CH}_2\text{Cl}_2/20^\circ\text{C}/1\text{ h}$; (ix) $\text{NH}_3(\text{g})/\text{i-PrOH}/100^\circ\text{C}/20\text{ h}$ (pressure vessel); (x) $\text{CH}_2=\text{CHCO}_2\text{H}/\text{Et}_3\text{N}$, then 2,4,6-triCIPhCOCl, then 72a/DMAP/THF/ $0^\circ\text{C}/15\text{ min}$ to rt/2 h.

stannane 59 with the 7-bromopyrido[3,2-*d*]pyrimidine (57) under palladium(0) catalysis gave the morpholinylbutenylpyrido[3,2-*d*]pyrimidine 60 in high yield (72%). This Stille coupling approach to the introduction of cationic solubilizing side chains in medicinal chemistry is novel to our knowledge and may prove to be a versatile method for analogue generation in the future, particularly lending itself to combinatorial methods. Direct displacement of the fluorine in pyrido[3,2-*d*]pyrimidine 60 by ammonia gave the required amine 61, while hydrogenation of 60 over PtO_2 to give fluoro derivative 62 and then ammonia treatment gave amine 63.

Synthesis of the 6-amino-7-alkoxy-pyrido[3,2-*d*]pyrimidines (72a-d) and the 6-methylamine (75) required first the synthesis of the key intermediate 7-methoxy-6-(methylthio)pyrido[3,2-*d*]pyrimidine (70a) (Scheme 4). This pivotal intermediate was obtained in four steps from 2-bromo-5-methoxy-6-(methylthio)-3-nitropyridine¹⁸ (64) in good overall yield. Initially direct displacement of the activated bromine with cyanide anion to give the nitrile 65 was followed by hydrolysis of the cyano moiety to give the carboxamide 66 which was reduced with iron dust to amine 67 and subsequently reacted with triethyl orthoformate to give pyrimidone 68. However low yields for the acid hydrolysis of nitrile 65 could not be overcome, so an alternate route was used. This involved iron dust reduction of 65 and then direct cyclization¹⁹ of the resulting aminopyridonitrile 69 in 88% formic acid containing a small amount of concentrated H_2SO_4 and gave the pyrimidone 68 in excellent yield. Chlorination in POCl_3 and reaction with 3-chloro-4-fluoroaniline gave the required intermediate 70a. Oxidation of the methylthio derivative 70a by *m*-CPBA to the methyl sulfoxide 71a, followed by reaction with ammonia, gave the 6-amino-7-methoxypyrido[3,2-*d*]pyrimidine (72a).

Selective cleavage of the methyl ether of 70a in the presence of the methylthio moiety was achieved with pyridine hydrochloride to give the phenol 73 (Scheme 5), which was then alkylated with either 3-bromopropanol or 2-bromoethylmethyl ether to give the alkoxy derivatives 74 and 70b, respectively. Mesylation of 74 and reaction with morpholine or 4-methylpiperazine

Scheme 5^a

^a (i) Pyridine-HCl/200–210 °C/8 min; (ii) Br(CH₂)₃OH or Br(CH₂)₂OMe/K₂CO₃/THF/DMF/reflux/1–2 h; (iii) Et₃N/MeCl/THF/DMF/0 °C/1 h, then morpholine or 4-Me-piperazine/reflux/4–5 days; (v) *m*-CPBA/CH₂Cl₂/rt/1 h or NaIO₄/1 N HCl/4 °C (for 70c,d); (vi) NH₃(g)/*i*-PrOH/100 °C/20 h (pressure vessel); (vii) CH₂=CHCO₂H/Et₃N, then 2,4,6-triClPhCOCl, then 72b–d/DMPAP/THF/0 °C/15 min to rt/2 h; (viii) MeNH₂/water/DMSO/110 °C/18 h (pressure vessel).

provided the morpholinopropoxy and 4-methylpiperazinylpropoxy derivatives 70c,d, respectively. Oxidation of the 7-alkoxy-6-methylthiopyrido[3,2-*d*]pyrimidine (70b) with *m*-CPBA gave the methylsulfinyl compound 71b, while sodium periodate oxidation of methylthio derivatives 70c,d gave their respective methylsulfinyl derivatives 71c,d. Tertiary amine *N*-oxide formation was prevented during the latter oxidation of amines 70c,d by performing the reaction in 1 N HCl. Reaction of 71b–d with ammonia provided the 6-amino derivatives 72b–d, while reaction of methyl sulfoxide 71c with methylamine provided the 6-methylamino derivative 75


Results and Discussion

The structures and physicochemical properties of the acrylamides studied are listed in Table 1, together with their potencies (IC_{50[app]} in nM) for inhibition of phosphorylation of a random glutamic acid/tyrosine copolymer substrate by isolated EGFR enzyme, inhibition of EGF-stimulated autophosphorylation of EGFR in A431 cells, and (for some examples) inhibition of heregulin-stimulated autophosphorylation of erbB2 in MDA-MB 453 cells.¹⁰ The type of inhibition of the isolated EGFR enzyme is also listed. Irreversible inhibition is defined¹⁴ as 80% or greater inhibition after a 10-min exposure to drug followed by drug washout and restimulation by EGF 8 h later. Drugs that produced 20–80% inhibition

were designated as partially irreversible (although in reality they can almost certainly fully inactivate the enzyme via alkylation given enough time). Those that produced less than 20% inhibition were classified as reversible. For compounds capable of rapid and complete alkylation of the enzyme, the IC₅₀ values derive essentially from titrating the enzyme activity in a stoichiometric manner and for this reason are designated as apparent IC₅₀s (IC_{50[app]}).¹⁴ The concentration of EGFR in the isolated enzyme assays is calculated at 1.18 nM and was held as constant as possible (<10% variation). The IC_{50[app]} values are an average of at least two separate determinations.

Cationic Side Chains at the 4'-Position of the Aniline. We have previously reported¹⁴ that in the 6-acrylamido-4-anilinoquinazoline series there is some bulk tolerance at the 4'-position of the aniline ring, with both phenyloxy and benzyloxy analogues retaining potent (IC₅₀s 4.8 and 4.2 nM, respectively) and fully irreversible inhibition of cellular autophosphorylation. Substitution at this position with relatively sterically nondemanding cationic side chains was therefore evaluated in a search for more soluble irreversible inhibitors. A 3'-bromo substituent, known to enhance the EGFR binding of reversible inhibitors,⁷ was also added. Both the 3'-bromo-4'-(*N,N*-dimethylaminomethyl) and 3'-bromo-4'-(*N,N*-dimethylaminoethoxy) analogues (5 and 6) showed improved aqueous solubility but were not irreversible inhibitors. They also showed a large reduction in potency in both the isolated enzyme (32–54-fold) and cellular (155–2850-fold) assays, compared to the unsubstituted quinazoline (3). There thus appears to be no tolerance at the 4'-position of the aniline ring for cationic side chains, with such substitutions resulting in a loss of binding affinity in the ATP binding domain of EGFR and a subsequent loss of delivery of the acrylamide moiety to the key cysteine of the active site.

Cationic Side Chains at the 7-Position of the Quinazoline. Both molecular modeling²⁰ and structure–activity relationship studies²¹ in the quinazoline and pyrido[*d*]pyrimidine series of reversible EGFR inhibitors have shown that there is tolerance for substitution at the 7-position with soluble cationic side chains. Compounds 7–19 explore the concept of substituting the optimal 6-acrylamide series of 4-anilinoquinazolines at the available 7-position with a series of solubilizing cationic side chains. Compounds 7–11, with a fixed 3'-Br substituent, employ a range of side chains of varying pK_a, found to be acceptable in previous studies of related reversible analogues,²¹ where they provided solubilities of >40 mM. The *N*-methylpiperazinylpropoxy (7), morpholinylpropoxy (8), and *N,N*-dimethylaminobutoxy (9) showed comparable activity (IC_{50[app]}s 2–4 nM) in both the isolated enzyme and cellular autophosphorylation assays, with the 1-imidazolylpropoxy (10) being about 3–6-fold less potent in the autophosphorylation assay. All were irreversible inhibitors. In contrast, the S(CH₂)₃-NEt₂ analogue 11 was only partially irreversible and much less effective in the autophosphorylation assay. The *N*-methylpiperazinylpropoxy and morpholinylpropoxy side chains were also employed in the 3'-Me series (compounds 13 and 14), since the parent compound (12) had been shown previously¹⁴ to be a potent irreversible inhibitor. Both compounds retained their

Table 1. Kinase Inhibition by Soluble 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-*d*]pyrimidine-6-acrylamides


no.	Fm	R	X	Y	mp (°C)	EGFR			<i>erbB2</i>
						enz ^a	auto ^b	type ^c	auto ^d
3	A	H	H		ref 14	0.70	2.7	irrev	5.7
5	A	CH ₂ NMe ₂	H		206	45	416	rev	
6	A	OCH ₂ CH ₂ NMe ₂	H		181–184.5	27	7693	rev	
7	B	O(CH ₂) ₃ 4-Mepip	H	Br	105–107	1.7	3	irrev	
8	B	O(CH ₂) ₃ morph	H	Br	170–172	3.6	5.3	irrev	6.4
9	B	O(CH ₂) ₄ NMe ₂	H	Br	112–115	3.9	7.9	irrev	
10	B	O(CH ₂) ₃ imidazolyl	H	Br	235–237	3.0	21	irrev	
11	B	S(CH ₂) ₃ NEt ₂	H	Br	77–79	0.78	196	partial	400
12	B	H	H	CH ₃	ref 14	0.42	4.7	irrev	22
13	B	O(CH ₂) ₃ 4-Mepip	H	CH ₃	60–66	2.0	18	irrev	
14	B	O(CH ₂) ₃ morph	H	CH ₃	69–72	1.5	27	irrev	
15	B	H	F	Br	ref 14	0.69	2.7	irrev	7.3
16	B	O(CH ₂) ₃ morph	F	Br	171–173	1.8	4.7	irrev	8.2
17	B	H	F	Cl	ref 14	0.75	3.1	irrev	4.3
18	B	O(CH ₂) ₃ morph	F	Cl	188–190	1.5	7.4	irrev	9.0
19	B	[O(CH ₂) ₂] ₂ (CH ₂) ₂ OH	F	Cl	131–132	1.7	ND	ND	
20	C	H	H		ref 14	0.75	18	irrev	12
21	C	CH=CH(CH ₂) ₂ morph	H		190–193	0.16	119	irrev	12
22	C	(CH ₂) ₄ morph	H		180–182	2.7	5100	irrev	>5000
23	C	OMe	H		226–228	0.95	291	partial	125
24	C	O(CH ₂) ₂ OMe	H		205–206	0.97	377	partial	
25	C	O(CH ₂) ₃ morph	H		185–186	1.5	434	irrev	189
26	C	O(CH ₂) ₃ morph	Me		176–178	20	88	partial	>200
27	C	O(CH ₂) ₃ 4-Mepip	H		166–168	6.6	264	partial	182

^a Concentration (IC_{50[app]} in nM) to inhibit by 50% the phosphorylation of a polyglutamic acid/tyrosine random copolymer by EGFR enzyme (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography). Values are the averages from at least two independent dose–response curves; variation was generally $\pm 15\%$. ^b Concentration (IC₅₀ in nM) to inhibit by 50% the phosphorylation of EGFR in A431 cells (detected by immunoblotting). ^c Irreversible inhibition is defined as >80% inhibition of formation of phosphorylated EGFR in A431 cells 8 h after washing cells free of the inhibitor. ^d IC₅₀ values (nM) for inhibition of autophosphorylation of *erbB2* (in MDA-MB 453 cells) in culture. Values are the average of at least two experiments.

ability to irreversibly inhibit EGFR, and while they were as potent as the 3'-Br derivatives in the isolated enzyme assay, they were somewhat less potent at inhibiting cellular autophosphorylation (IC₅₀s 18 and 27 nM, respectively).

Two 4'-F analogues with the morpholinylpropoxy solubilizing group (**16** and **18**) were also studied (using respectively 3'-Br and 3'-Cl binding enhancers), since work by others²² with reversible dianilinophthalimide EGFR inhibitors has shown that a *p*-F substituent provides longer in vivo half-lives, possibly by blocking metabolism. Both of these compounds had similar potencies to their nonsolubilized analogues (**15** and **17**, respectively) and also compared favorably to the corresponding nonfluorinated analogue **8**, suggesting that better metabolic stability can be provided without compromising inhibitory potency. Compound **19**, which explored the use of a neutral oxygenated solubilizing function, showed reasonably potent enzyme inhibitory properties but no distinct solubility advantage and was therefore not studied further.

The quinazolines **8**, **16**, and **18**, bearing cationic side chains, show excellent potency for inhibition of *erbB2* autophosphorylation in MDA-MB 453 cells (IC₅₀s 6.4, 8.2, and 9.0 nM, respectively). We have previously reported¹³ an acrylamide-bearing quinazoline capable of covalently modifying both EGFR and *erbB2*, both of

which have the key cysteine 773 at the entrance of their ATP binding domain. It therefore seems likely that the excellent activity shown by quinazolines **8**, **16**, and **18** against *erbB2* is due also to irreversible inhibition of this enzyme. These compounds therefore represent a novel class of potent, soluble, irreversible inhibitors of the larger EGFR family of tyrosine kinases.

Cationic Side Chains at the 7-Position of the Pyrido[3,2-*d*]pyrimidine. Because the pyrido[3,2-*d*]pyrimidines are also potent reversible inhibitors of EGFR,⁹ it was of interest to see whether 6-acrylamide analogues of this additional series were also irreversible inhibitors. The pyrido[3,2-*d*]pyrimidine **20** was therefore prepared¹⁴ and shown to be an irreversible inhibitor, with similar potency against the isolated enzyme to the corresponding quinazoline (**17**) (IC_{50[app]}s both 0.75 nM), but with slightly lower potency in the autophosphorylation assay (IC₅₀s 18 and 3.1 nM, respectively). The pyrido[3,2-*d*]pyrimidine chromophore also provided an opportunity to introduce solubilizing side chains at the 7-position while retaining the optimally positioned 6-acrylamide,^{13,14} and a small series of analogues of **20** with solubilizing 7-substituents were prepared. The "carbon-linked" morpholinylbutyl derivative (**22**) showed good activity against the isolated enzyme (IC_{50[app]} 2.8 nM) but a large loss of potency in the cellular autophosphorylation assays against EGFR and *erbB2* (IC₅₀s 5100

and >5000 nM, respectively). However, the corresponding unsaturated derivative (**21**) was the most potent inhibitor of the isolated EGFR enzyme in the series, with an $IC_{50[app]}$ of 0.16 nM, possibly suggesting an advantage in terms of potency when the 7-side chain is conformationally restrained close to the chromophore ring system. Derivative **21** was less active in the EGFR autophosphorylation assay in A431 cells (although not to the same extent as derivative **22**), with an IC_{50} of 119 nM, although it had high potency (IC_{50} 12 nM) in the cellular *erbB2* autophosphorylation assay (in MDA-MB 453 cells), showing the largest differential toward *erbB2* of all the compounds evaluated. The general loss of potency for the "carbon-linked" solubilized pyrido[3,2-*d*]pyrimidines in the cellular assays, except for the *erbB2* potency of compound **21**, suggests these compounds may suffer from metabolism, transport, permeability, or stability problems in a cell-line-specific manner.

One possibility was that the "carbon-linked" soluble side chains were undergoing cellular metabolism at the benzylic position. This was consistent with the saturated derivative (**22**) being less potent than the unsaturated derivative (**21**). Therefore a series of "oxygen-linked" direct pyrido[3,2-*d*]pyrimidine analogues of quinazoline **18** were prepared. However, while these (**23–27**) were generally also potent inhibitors of the isolated EGFR enzyme, they were much less effective than the quinazolines in inhibiting EGFR and *erbB2* autophosphorylation in cells and were generally classed as only partially irreversible in the 8-h washout assay.

Comparisons of Quinazoline and Pyrido[3,2-*d*]pyrimidine Analogues. The reasons for the loss of cellular activity of the pyrido[3,2-*d*]pyrimidines compared with the corresponding quinazolines were sought in a number of comparative studies. The binding stoichiometry and the site(s) of interaction between EGF receptor tyrosine kinase and the morpholinylbutylpyrido[3,2-*d*]pyrimidine **22** was determined through the use of electrospray ionization mass spectrometry (ESI-MS),²³ along with that of the quinazoline **18** as a positive control.¹³ The molecular weight of the EGF receptor complexed with the compounds, as measured by ESI-MS, was approximately 485 Da higher than the apo-protein; the mass difference is consistent with a covalent 1:1 protein:drug complex.¹³ A small amount (10–20% relative abundance) of 1:2 protein:drug complex was also observed. Trypsin digestion of the drug-bound protein and analyses by LC-ESI tandem mass spectrometry (MS/MS) identified cysteine 773 as the predominant site of interaction for both compounds, suggesting that a change in the target site was not the reason for the different activities.

The absorptive and secretory transport of the quinazoline **18** and the pyrido[3,2-*d*]pyrimidine **25** were compared in Caco-2 cells²⁴ (Table 2). Activity of P-gp in the Caco-2 cells was confirmed by substantially greater basolateral-to-apical (B→A) versus apical-to-basolateral (A→B) permeability of [³H]vinblastine, a known substrate of P-gp^{25,26} (Table 2). Compounds **18** and **25** both showed high permeability in Caco-2 cells (greater than the experimentally determined permeability of [³H]-metoprolol, which is 90–95% absorbed in humans). The B→A/A→B ratios of 1.2 and 1.36 for **18** and **25**, respectively, suggest that efflux is not a concern with either

Table 2. Absorptive and Secretory Transport of **18** and **25** in Caco-2 Cells in Comparison to Metoprolol (90–95% absorbed) and Vinblastine (P-gp substrate)

compd	permeability × 10 ⁶ (cm/s) ^a		permeability limited?	efflux limited?
	absorption	secretion		
18	49.3 ± 8.92	59.1 ± 4.81	no	no
25	59.6 ± 7.38	81.2 ± 4.80	no	no
metoprolol	21.4 ± 3.26	38.2 ± 7.47	no	no
vinblastine	1.54 ± 1.91	12.5 ± 4.47	yes	yes

^a Data are reported as means ± SD from $n = 3$. Values for [¹⁴C]mannitol (leakage marker) ranged from 0.74 to 0.761 × 10⁻⁶ cm/s for A→B studies and from 1.13 to 1.99 × 10⁻⁶ cm/s for B→A studies.




Figure 1. Inhibition of the secretory transport of vinblastine in Caco-2 cells by compounds **18** and **25**, in comparison to the known inhibitor cyclosporin A (mean ± SD, $n = 3$).

of these compounds. The effect of **18** and **25** on inhibition of the secretory transport of vinblastine was also carried out in comparison with the known inhibitor cyclosporin A (Figure 1). Even though none of the inhibitory results were significantly different from the control, both compounds are likely inhibitors of P-gp, as evidenced by their similar effect on vinblastine efflux as compared with cyclosporin A.^{27,28}

The structural similarity and above similar biochemical properties of **25** compared with **18** (which showed potent inhibition of autophosphorylation) make the poor cellular activity of the former difficult to understand. The Caco-2 studies show that **25** has cellular permeability and efflux characteristics similar to those of **18**.

Another possibility for the poor cellular activity of the pyrido[3,2-*d*]pyrimidines (e.g., **25** versus **18**) was lower stability of the acrylamide moiety in the former. Accelerated cleavage of the acrylamide group of **25**, either by cellular amidases or a hydrolytic mechanism to give the 6-amino derivative **72c**, may lower its activity (**72c** has low potency in autophosphorylation assays, with an IC_{50} for inhibition of heregulin-stimulated *erbB2* autophosphorylation in MDA-MB 453 cells of 430 nM). This was explored by comparative stability studies of **25** and **18**. Solutions of these compounds in phosphate buffers

Table 3. In Vivo Antitumor Activities of Selected Soluble 4-Anilinoquinazolin- and 4-Anilino-6-acrylamides in A431 Xenografts

no.	dose ^a (mg/kg)	schedule ^b	weight change (g)	T/C (%) last therapy day ^c	T-C ^d (days)
8	10	ip, b.i.d., days 13-26	+	18	21.5
	60	po, days 10-24	-1.6	0	29.8
18	18	po, days 10-24	-1.0	0	41.3
	5*	po, days 10-24	-0.4	4	53.2
25	20*	po, days 15-19, 22-26, 29-33	-0.5	69	9.3

^a Maximum tolerated dose (not exceeding LD₁₀). ^b Compounds were administered in solution as the isethionate salts (**8** and **18**) or as a solution in lactate buffer (**25**), either intraperitoneally or orally on the indicated schedules. (Tumors were implanted sc into the right axilla of mice on day 0.) ^c Ratio of median treated tumor mass/median control tumor mass \times 100. ^d The difference in days for treated (T) and control (C) tumors to reach 750 mg. * Not a maximum tolerated dose.

at pH 2.6, 6.67, and 10.75 were kept at 37 °C and monitored by HPLC for 24 h for formation of the corresponding 6-amine hydrolysis products (**72c** and **50b**, respectively). The quinazoline **18** was stable at all pH levels. In contrast, while the pyrido[3,2-*d*]pyrimidine **25** was stable at pH 2.6 and 6.67, it was quite unstable at pH 10.75, hydrolyzing to the corresponding amine **72c** with a half-life of about 2.5 h. Further support for this hypothesis was provided by the *N*-methylacrylamide **26** (the direct analogue of **25**). While **26** showed reduced potency in the isolated enzyme assay (IC₅₀[app] 20 nM) and only partially irreversible inhibition (consistent with a reduced binding affinity in the ATP binding domain due to *N*-methylation), it showed improved cellular potency against EGFR autophosphorylation (IC₅₀ 88 nM compared to **25** with IC₅₀ 434 nM). This is consistent with higher metabolic stability. Finally, mass spectral studies of the metabolism of the two compounds in A431 cells in culture showed that **25** was converted much more rapidly than **18** to the corresponding glutathione adducts. This higher apparent reactivity of the acrylamide in the pyrido[3,2-*d*]pyrimidine analogue may also contribute to the lower effectiveness of this compound in cells.

In Vivo Activity. The quinazolines **8** and **18** and the pyrido[3,2-*d*]pyrimidine **25** were evaluated against A431 xenografts in mice, and the results are given in Table 3. Both **8** and **18** showed impressive activity when dosed orally for 14 days, but the derivative **18** was much more potent (optimal dose 5 mg/kg/day) compared to the other analogues. The pyrido[3,2-*d*]pyrimidine **25** was only minimally effective, indicating a very low dose potency for this compared to both the other derivatives tested even though it was equally soluble. The essentially equivalent antitumor activity for **18** at the two dose levels shown in Table 3 suggests that this compound might have a good therapeutic index. Weight loss, as an indicator of compound-induced toxicity, was minimal in the experimental animals, being less than 10% at tolerated dose levels.

Conclusions

New and feasible synthetic routes to 4-anilino-6-acrylamides bearing solubilizing 7-alkylamino and 7-alkoxyamino side chains have been developed. Stille coupling of stannanes with the 7-bro-

mopyrido[3,2-*d*]pyrimidine (**57**) under palladium(0) catalysis was a facile way of introducing the 7-alkylamino side chains and could be more broadly used in medicinal chemistry. The solubilizing side chains do not alter the previously determined binding mode of these compounds to the EGFR enzyme: binding at the ATP site and alkylating cysteine 773. They were potent and irreversible inhibitors of the isolated enzyme, and the quinazolines were also potent inhibitors of both EGFR and *erbB2* autophosphorylation in cells, although the corresponding pyrido[3,2-*d*]pyrimidines (both 7-alkylamine and 7-alkoxyamine substituted) were less effective in the cellular assays. The reason for this is most likely due to differences in the chemistry of the acrylamide side chain, which in the pyrido[3,2-*d*]pyrimidines was less stable to both chemical hydrolysis at high pH to the amine (this may be a marker for more rapid hydrolysis by amidases) and cellular metabolism to the glutathione conjugate.

The quinazoline propoxymorpholide **18** showed superior in vivo antitumor activity to previous nonsolubilized analogues, giving growth delays in A431 xenografts exceeding 50 days following oral administration. This compound (as the dihydrochloride salt, CI 1033) has been selected for clinical evaluation.¹⁵

Experimental Section

Analyses were performed by the Microchemical Laboratory, University of Otago, Dunedin, NZ, or by Parke-Davis Pharmaceutical Research Analytical Department. Melting points were determined using an Electrothermal model 9200 or Gallenkamp digital melting point apparatus and are as read. NMR spectra were measured on Bruker DRX-400 or Varian Unity 400-MHz spectrometers and referenced to Me₄Si. Mass spectra were recorded on either a Varian VG 7070 spectrometer at nominal 5000 resolution or a Finnigan MAT 900Q spectrometer.

N-[4-[N-[3-Bromo-4-(dimethylaminomethyl)phenyl]amino]quinazolin-6-yl]acrylamide (5). Example of the Method of Scheme 1. To a solution of 2-bromo-4-nitrobenzyl bromide¹⁶ (**28**) (7.00 g, 23.7 mmol) in MeOH (100 mL) was added excess dimethylamine (15 mL, 40% solution in water). After 1 h at room temperature the reaction mixture was concentrated under reduced pressure, diluted with water and extracted with EtOAc. The combined organic extracts were then extracted with 1 N HCl which was then basified with concentrated NH₄OH and extracted with EtOAc. The organic layer was dried (Na₂SO₄) and concentrated under reduced pressure before being chromatographed on silica gel eluting with EtOAc to give 2-bromo-4-nitro-*N,N*-dimethylbenzylamine (**29**) as an oil (5.0 g, 62%): ¹H NMR [(CD₃)₂SO] δ 8.40 (d, *J* = 2.4 Hz, 1 H, H-3), 8.24 (dd, *J* = 8.5, 2.5 Hz, 1 H, H-5), 7.75 (d, *J* = 8.5 Hz, 1 H, H-6), 3.56 (s, 2 H, ArCH₂N), 2.24 (s, 6 H, N(CH₃)₂). HRMS (EI) Calculated for C₉H₁₁⁷⁹BrN₂O₂: 258.0004. Found: 258.0003.

Iron powder (4.00 mol equiv, 5.46 g; freshly washed with 1 N HCl followed by distilled water) was added in portions to a refluxing solution of **29** (6.00 g, 24.5 mmol) in EtOH/H₂O (2:1, 180 mL) containing glacial AcOH (6.0 mL). The resulting suspension was heated at reflux with vigorous stirring for 20 min, then cooled, basified with concentrated NH₄OH and filtered through a pad of Celite. The Celite was washed with EtOH, and the combined filtrate was concentrated under reduced pressure, diluted with water and extracted with EtOAc. The combined organic extracts were dried over anhydrous Na₂SO₄, concentrated under reduced pressure, and chromatographed on grade III alumina, eluting with EtOAc/hexane (1:2), to give 4-amino-2-bromo-*N,N*-dimethylbenzylamine (**30**) (5.03 g, 96%), which was used directly: ¹H NMR [(CD₃)₂SO] δ 7.01 (d, *J* = 8.2 Hz, 1 H, H-6), 6.77 (d, *J* = 2.2 Hz, 1 H, H-3), 6.51 (dd, *J* = 8.2, 2.2 Hz, 1 H, H-5), 5.26 (s, 2 H, NH₂), 3.26 (s, 2 H, ArCH₂N), 2.12 (s, 6 H, N(CH₃)₂).

To a solution of 2-bromo-4-nitrophenol (**31**) (2.50 g, 12.3 mmol) in DMF (30 mL) were added 2-dimethylaminoethyl chloride hydrochloride (2.65 g, 18.4 mmol) and K_2CO_3 (5.08 g, 36.8 mmol). The resulting suspension was heated at 100 °C with stirring for 2 h before further 2-dimethylaminoethyl chloride hydrochloride (1.0 g) was added. After a further 2 h the DMF was removed under reduced pressure, the residue was diluted with NH_4OH and extracted with EtOAc. The combined organic extracts were then dried (Na_2SO_4) and concentrated under reduced pressure before being chromatographed on grade III alumina, eluting with EtOAc/hexane (1:2), to give 2-bromo-1-[2-(dimethylamino)ethoxy]-4-nitrobenzene (**32**) (0.96 g, 27%) as a glassy solid: 1H NMR [$(CD_3)_2SO$] δ 8.42 (d, J = 2.7 Hz, 1 H, H-3), 8.26 (dd, J = 9.2, 2.7 Hz, 1 H, H-5), 7.36 (d, J = 9.2 Hz, 1 H, H-6), 4.30 (t, J = 5.6 Hz, 2 H, OCH_2CH_2N), 2.72 (t, J = 5.6 Hz, 2 H, OCH_2CH_2N), 2.25 (s, 6 H, $N(CH_3)_2$). HRMS (EI) Calculated for $C_{10}H_{13}^{79}BrN_2O_3$: 288.01095. Found: 288.01097.

A solution of **32** (0.96 g, 3.39 mmol) in EtOAc/MeOH (60 mL, 5:1) was hydrogenated at 60 psi over Pt-C for 25 min before being filtered through Celite, concentrated and chromatographed on grade III alumina, eluting with EtOAc/hexane (1:1), to give 4-amino-2-bromo-1-[2-(dimethylamino)ethoxy]benzene (**33**) (0.49 g, 56%), which was used directly: 1H NMR [$(CD_3)_2SO$] δ 10.47 (br s, 1 H, NH), 9.66 (d, J = 2.5 Hz, 1 H, H-5), 8.77 (s, 1 H, H-2), 8.57 (dd, J = 9.2, 2.5 Hz, 1 H, H-7), 8.21 (d, J = 2.0 Hz, 1 H, H-2'), 7.95 (d, J = 9.2 Hz, 1 H, H-8), 7.91 (dd, J = 8.5, 2.0 Hz, 1 H, H-6'), 7.49 (d, J = 8.5 Hz, 1 H, H-5'), 3.46 (s, 2 H, $CH_2N(CH_3)_2$), 2.22 (s, 6 H, $N(CH_3)_2$). Anal. ($C_{17}H_{18}BrN_5O_2 \cdot 1.5H_2O$) C, H, N.

A suspension of 6-nitroquinazoline (3.50 g, 18.5 mmol) in neat $SOCl_2$ (30 mL) containing 2 drops of DMF was refluxed for 3 h until it became clear. The excess $SOCl_2$ was removed under reduced pressure, and dry benzene was added and then evaporated under reduced pressure to remove all traces of $SOCl_2$. The resulting crude 4-chloro-6-nitroquinazoline¹⁷ (**34**) was dissolved in dry CH_2Cl_2 (50 mL) and washed twice with saturated Na_2CO_3 , and this solution was then added to a solution of 4-amino-2-bromo-*N,N*-dimethylbenzylamine (**30**) (20.3 mmol, 4.64 g) in *i*-PrOH (60 mL) containing Et_3N (excess, 7.0 mL). The resulting reaction mixture was heated at reflux for 3 h and then concentrated under reduced pressure, diluted with water and extracted with EtOAc. The combined organic extracts were dried over anhydrous Na_2SO_4 , concentrated under reduced pressure and chromatographed on silica gel eluting with CH_2Cl_2 /EtOAc (1:1) to MeOH/ CH_2Cl_2 /EtOAc (2:9:9) to give 4-[*N*-(3-bromo-4-(dimethylaminomethyl)phenyl)amino]-6-nitroquinazoline (**35**) (0.62 g, 8%): mp (CH_2Cl_2) 198–200 °C; 1H NMR [$(CD_3)_2SO$] δ 10.47 (br s, 1 H, NH), 9.66 (d, J = 2.5 Hz, 1 H, H-5), 8.77 (s, 1 H, H-2), 8.57 (dd, J = 9.2, 2.5 Hz, 1 H, H-7), 8.21 (d, J = 2.0 Hz, 1 H, H-2'), 7.95 (d, J = 9.2 Hz, 1 H, H-8), 7.91 (dd, J = 8.5, 2.0 Hz, 1 H, H-6'), 7.49 (d, J = 8.5 Hz, 1 H, H-5'), 3.46 (s, 2 H, $CH_2N(CH_3)_2$), 2.22 (s, 6 H, $N(CH_3)_2$). Anal. ($C_{17}H_{18}BrN_5O_2 \cdot 1.5H_2O$) C, H, N.

Iron dust reduction of **35** (0.52 g, 1.29 mmol) in EtOH/ H_2O (2:1, 50 mL) containing glacial AcOH (0.7 mL) as described above gave, after chromatography on grade III alumina, eluting with EtOAc to MeOH/EtOAc (5:95), 6-amino-4-[*N*-(3-bromo-4-(dimethylaminomethyl)phenyl)amino]quinazoline (**37**) (0.32 g, 67%): mp (trihydrochloride salt from MeOH/ Et_2O) 296 °C dec; 1H NMR [trihydrochloride salt, $(CD_3)_2SO$] δ 11.37 (s, 1 H, NH), 11.17 (br s, 1 H, NH), 8.81 (s, 1 H, H-2), 8.25 (d, J = 2.0 Hz, 1 H, H-2' or H-5), 8.02 (d, J = 8.4 Hz, 1 H, H-5'), 7.96 (dd, J = 8.4, 2.0 Hz, 1 H, H-6'), 7.87 (d, J = 9.0 Hz, 1 H, H-8), 7.78 (d, J = 2.1 Hz, 1 H, H-2' or H-5), 7.53 (dd, J = 9.0, 2.2 Hz, 1 H, H-7), 5.46 (br s, 4 H, NH), 4.47 (d, J = 5.3 Hz, 2 H, $C_7H_2N^+H(CH_3)_2$), 2.79 (d, J = 4.6 Hz, 6 H, $N^+H(CH_3)_2$). Anal. ($C_{17}H_{18}BrN_5 \cdot 3HCl \cdot 1.5H_2O$) C, H, N.

1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI-HCl) (2 mol equiv, 1.31 mmol, 250 mg) was added to a stirred solution of **37** (243 mg, 0.65 mmol), acrylic acid (4 mol equiv, 2.61 mmol, 179 μ L), and pyridine (excess, 1.0 mL) in DMA (15 mL) under N_2 . After 2 h at room temperature, the reaction mixture was concentrated under reduced pressure before being diluted with saturated $NaHCO_3$, the resulting

suspension was then extracted with EtOAc. The combined organic extracts were washed with brine, dried over anhydrous Na_2SO_4 and concentrated under reduced pressure before being chromatographed on silica gel eluting with EtOAc/ CH_2Cl_2 (1:1) to MeOH/ CH_2Cl_2 /EtOAc (3:7:10), to give **5** (115 mg, 41%): mp (CH_2Cl_2) 206 °C dec; 1H NMR [$(CD_3)_2SO$] δ 10.52 (s, 1 H, CONH), 9.91 (s, 1 H, NH), 8.82 (d, J = 2.1 Hz, 1 H, H-5), 8.58 (s, 1 H, H-2), 8.20 (d, J = 2.1 Hz, 1 H, H-2'), 7.90 (dd, J = 8.9, 2.1 Hz, 1 H, H-7), 7.87 (dd, J = 8.4, 2.1 Hz, 1 H, H-6'), 7.80 (d, J = 8.9 Hz, 1 H, H-8), 7.44 (d, J = 8.4 Hz, 1 H, H-5'), 6.54 (dd, J = 17.0, 10.1 Hz, 1 H, $CH=CH_2$), 6.35 (dd, J = 17.0, 1.9 Hz, 1 H, $CH=CH_2$), 5.84 (dd, J = 10.1, 1.9 Hz, 1 H, $CH=CH_2$), 3.46 (s, 2 H, $CH_2N(CH_3)_2$), 2.22 (s, 6 H, $N(CH_3)_2$). Anal. ($C_{20}H_{20}BrN_5O \cdot H_2O$) C, H, N.

N-(4-[*N*-(3-Bromo-4-[2-(dimethylamino)ethoxy]phenyl)-amino]quinazolin-6-yl)acrylamide (**6**). Reaction of 4-chloro-6-nitroquinazoline¹⁷ (**34**) with 4-amino-2-bromo-1-[2-(dimethylamino)ethoxy]benzene (**33**) gave crude **36**, which was reduced with iron dust to crude **38**. EDCI-HCl-promoted acylation of this as described above gave **6**: mp (CH_2Cl_2 /hexane) 181–184.5 °C; 1H NMR [$(CD_3)_2SO$] δ 10.50 (s, 1 H, CONH), 9.81 (s, 1 H, NH), 8.80 (br s, 1 H, H-5), 8.52 (s, 1 H, H-2), 8.09 (d, J = 2.6 Hz, 1 H, H-2'), 7.88 (dd, J = 1.9, 9.0 Hz, 1 H, H-7), 7.78 (partially obscured d, J = 9.0 Hz, 1 H, H-8), 7.76 (partially obscured dd, J = 9.0, 2.6 Hz, 1 H, H-6'), 7.17 (d, J = 9.0 Hz, 1 H, H-5'), 6.53 (dd, J = 16.9, 10.1 Hz, 1 H, $CH=CH_2$), 6.35 (dd, J = 16.9, 1.8 Hz, 1 H, $CH=CH_2$), 5.84 (dd, J = 10.1, 1.8 Hz, 1 H, $CH=CH_2$), 4.14 (t, J = 5.7 Hz, 2 H, OCH_2CH_2N), 2.69 (t, J = 5.7 Hz, 2 H, OCH_2CH_2N), 2.27 (s, 6 H, $N(CH_3)_2$). Anal. ($C_{21}H_{22}BrN_5O_2 \cdot 0.25H_2O$) C, H, N.

N-(4-[*N*-(3-Bromophenyl)amino]-7-[3-(4-methyl-1-piperazinyl)propoxy]quinazolin-6-yl)acrylamide (**7**). Example of the Method of Scheme 2. Sodium metal (0.30 g, 13.2 mmol) was added to a solution of 3-(4-methyl-1-piperazinyl)-1-propanol (1.39 g, 8.81 mmol) in THF (40 mL) under N_2 , and the resulting suspension was stirred at 20 °C for 2 h and then cannulated into a solution of 4-[(3-bromophenyl)amino]-7-fluoro-6-nitroquinazoline²⁹ (**39**) (0.80 g, 2.20 mmol) in THF (30 mL) under N_2 . The reaction mixture was refluxed for 18 h before the solvent was partially removed under reduced pressure and the residue was diluted with water and extracted with EtOAc. The combined organic extracts were dried (Na_2SO_4), concentrated under reduced pressure and chromatographed on silica gel, eluting with MeOH/ CH_2Cl_2 /EtOAc (1:9:10) to MeOH/ CH_2Cl_2 /EtOAc (2:3:5) to give 4-[*N*-(3-bromophenyl)amino]-7-[3-(4-methyl-1-piperazinyl)propoxy]-6-nitroquinazoline (**43a**) (0.36 g, 33%): mp (trihydrochloride salt) (MeOH/ Et_2O) 233 °C dec; 1H NMR [free base, $(CD_3)_2SO$] δ 10.12 (s, 1 H, NH), 9.24 (s, 1 H, H-5), 8.69 (s, 1 H, H-2), 8.19 (br s, 1 H, H-2'), 7.88 (br d, J = 7.8 Hz, 1 H, H-6'), 7.47 (s, 1 H, H-8), 7.38 (t, J = 7.8 Hz, 1 H, H-5'), 7.34 (ddd, J = 7.8, 1.3, 1.3 Hz, 1 H, H-4'), 4.33 (t, J = 6.1 Hz, 2 H, $CH_2CH_2CH_2O$), 2.45 (t, J = 7.0 Hz, 2 H, $NCH_2CH_2CH_2$), 2.42–2.29 (br s, 8 H, piperazinyl methylene), 2.15 (s, 3 H, CH_3N), 1.92 (quintet, J = 6.7 Hz, 2 H, $CH_2CH_2CH_2$). Anal. ($C_{22}H_{25}BrN_6O_3 \cdot 3HCl \cdot H_2O$) C, H, N, Cl.

Reduction of **43a** (0.31 g, 0.62 mmol) with Fe powder in EtOH/ H_2O (2:1, 50 mL) containing glacial AcOH (1.0 mL) as above, followed by chromatography of the product on grade III alumina, eluting with MeOH/EtOAc (5:95), gave 6-amino-4-[*N*-(3-bromophenyl)amino]-7-[3-(4-methyl-1-piperazinyl)propoxy]quinazoline (**47a**) (238 mg, 82%): mp (CH_2Cl_2) 171–172 °C; 1H NMR [$(CD_3)_2SO$] δ 9.36 (s, 1 H, NH), 8.38 (s, 1 H, H-2), 8.22 (t, J = 1.9 Hz, 1 H, H-2'), 7.86 (ddd, J = 8.2, 1.9, 0.8 Hz, 1 H, H-6'), 7.40 (s, 1 H, H-8), 7.30 (t, J = 8.0 Hz, 1 H, H-5'), 7.20 (ddd, J = 8.3, 1.9, 1.0 Hz, 1 H, H-4'), 7.09 (s, 1 H, H-5), 5.34 (s, 2 H, NH_2), 4.19 (t, J = 6.2 Hz, 2 H, $CH_2CH_2CH_2O$), 2.49 (observed t, J ~ 7 Hz, 2 H, $NCH_2CH_2CH_2$), 2.43–2.29 (br s, 8 H, piperazinyl methylene), 2.16 (s, 3 H, CH_3N), 1.97 (quintet, J = 6.8 Hz, 2 H, $CH_2CH_2CH_2$). Anal. ($C_{22}H_{27}BrN_6O \cdot 1.25H_2O$) C, H, N.

A stirred solution of **47a** (223 mg, 0.47 mmol), acrylic acid (6 mol equiv, 2.84 mmol, 195 μ L) and Et_3N (excess, 1.0 mL) in DMA (20 mL) under N_2 was treated with EDCI-HCl (3 mol

equiv, 1.42 mmol, 273 mg). Standard workup, followed by chromatography on grade III alumina, eluting with EtOAc/hexane (1:1) to MeOH/EtOAc (2:98), gave **7** (145 mg, 58%): mp (CH₂Cl₂/Et₂O/hexane) 105–107 °C; ¹H NMR [(CD₃)₂SO] δ 9.78 (s, 1 H, CONH), 9.61 (s, 1 H, NH), 8.89 (s, 1 H, H-5), 8.56 (s, 1 H, H-2), 8.17 (t, *J* = 1.9 Hz, 1 H, H-2'), 7.87 (br d, *J* = 8.3 Hz, 1 H, H-6'), 7.34 (t, *J* = 8.3 Hz, 1 H, H-5'), 7.28 (s, 1 H, H-8), 7.27 (observed ddd, *J* ~ 8, ~ 1, ~ 1 Hz, 1 H, H-4'), 6.72 (dd, *J* = 17.0, 10.3 Hz, 1 H, CH=CH₂), 6.32 (dd, *J* = 17.0, 1.9 Hz, 1 H, CH=CH₂), 5.83 (dd, *J* = 10.3, 1.9 Hz, 1 H, CH=CH₂), 4.26 (t, *J* = 6.3 Hz, 2 H, CH₂CH₂CH₂O), 2.47 (t, *J* = 7.1 Hz, 2 H, NCH₂CH₂CH₂), 2.42–2.27 (br s, 8 H, piperaziny methylene), 2.15 (s, 3 H, CH₃N), 1.98 (quintet, *J* = 6.7 Hz, 2 H, CH₂CH₂CH₂). Anal. (C₂₅H₂₈BrN₆O₂·0.5H₂O) C, H, N.

N-[4-[**N**-(3-Bromophenyl)amino]-7-[3-(4-morpholinyl)propoxy]quinazolin-6-yl]acrylamide (**8**). Sodium metal (0.63 g, 27.6 mmol) was added to a solution of 3-(4-morpholinyl)-1-propanol (3.20 g, 22.0 mmol) in THF (60 mL) under N₂. The resulting suspension was stirred at 20 °C for 2 h and then cannulated into a solution of **39**²⁹ (2.0 g, 5.51 mmol) in THF (50 mL) under N₂. Identical reaction procedure and workup as above gave, after chromatography on silica gel eluting with CH₂Cl₂/EtOAc (1:1) to MeOH/CH₂Cl₂/EtOAc (2:3:5), 4-[**N**-(3-bromophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-nitroquinazoline (**43b**) (1.75 g, 65%): mp (MeOH) 216–220 °C; ¹H NMR [(CD₃)₂SO] δ 10.12 (s, 1 H, NH), 9.24 (s, 1 H, H-5), 8.69 (s, 1 H, H-2), 8.19 (t, *J* = 1.8 Hz, 1 H, H-2'), 7.88 (ddd, *J* = 8.0, 1.4, 1.4 Hz, 1 H, H-6'), 7.49 (s, 1 H, H-8), 7.38 (t, *J* = 8.0 Hz, 1 H, H-5'), 7.34 (ddd, *J* = 8.0, 1.4, 1.4 Hz, 1 H, H-4'), 4.35 (t, *J* = 6.2 Hz, 2 H, CH₂CH₂CH₂O), 3.58 (t, *J* = 4.6 Hz, 4 H, morpholino methylene), 2.45 (t, *J* = 7.0 Hz, 2 H, NCH₂CH₂CH₂), 2.37 (m, 4 H, morpholino methylene), 1.94 (quintet, *J* = 6.6 Hz, 2 H, CH₂CH₂CH₂); ¹³C NMR δ 157.76, 157.26, 153.76, 153.21, 140.32, 138.86, 130.37, 126.38, 124.26, 121.70, 121.13, 120.72, 110.11, 107.88, 67.87, 66.13 (×2), 54.42, 53.28 (×2), 25.30. Anal. (C₂₁H₂₂BrN₅O₄·0.75H₂O) C, H, N.

Reduction of **43b** (1.50 g, 3.07 mmol) with Fe powder in EtOH/H₂O (2:1, 80 mL) containing glacial AcOH (2.0 mL) as above, followed by chromatography of the product on grade III alumina eluting with CH₂Cl₂/EtOAc (1:1) to MeOH/EtOAc (2:98), gave 6-amino-4-[**N**-(3-bromophenyl)amino]-7-[3-(4-morpholinyl)propoxy]quinazoline (**47b**) (1.08 g, 77%): mp (EtOAc/hexane) 158–160 °C; ¹H NMR [(CD₃)₂SO] δ 9.37 (s, 1 H, NH), 8.40 (s, 1 H, H-2), 8.24 (t, *J* = 1.9 Hz, 1 H, H-2'), 7.86 (ddd, *J* = 8.2, 1.9, 0.9 Hz, 1 H, H-6'), 7.42 (s, 1 H, H-8), 7.30 (t, *J* = 8.2 Hz, 1 H, H-5'), 7.21 (ddd, *J* = 8.2, 1.9, 0.9 Hz, 1 H, H-4'), 7.09 (s, 1 H, H-5), 5.36 (s, 2 H, NH₂), 4.20 (t, *J* = 6.2 Hz, 2 H, CH₂CH₂CH₂O), 3.59 (t, *J* = 4.6 Hz, 4 H, morpholino methylene), 2.50 (t, *J* = 7.3 Hz, 2 H, NCH₂CH₂CH₂), 2.39 (m, 4 H, morpholino methylene), 1.99 (quintet, *J* = 6.7 Hz, 2 H, CH₂CH₂CH₂); ¹³C NMR δ 154.88, 151.94, 150.19, 144.84, 141.94, 138.50, 130.16, 124.66, 123.02, 121.09, 119.65, 110.42, 106.37, 100.81, 66.45, 66.14 (×2), 54.77, 53.29 (×2), 25.50. Anal. (C₂₁H₂₄BrN₅O₂·0.25H₂O) C, H, N.

A stirred solution of **47b** (0.50 g, 1.09 mmol), acrylic acid (6 mol equiv, 6.54 mmol, 449 μL), and Et₃N (excess, 2.0 mL) in DMF (20 mL) under N₂ was treated with EDCI·HCl (3 mol equiv, 3.27 mmol, 627 mg). The standard procedure above was followed to give, after chromatography on grade III alumina eluting with EtOAc/hexane (9:1) to MeOH/EtOAc (2:98), **8** (329 mg, 59%): mp (EtOAc/Et₂O/hexane) 170–172 °C; ¹H NMR [(CD₃)₂SO] δ 9.78 (s, 1 H, CONH), 9.62 (s, 1 H, NH), 8.89 (s, 1 H, H-5), 8.56 (s, 1 H, H-2), 8.18 (t, *J* = 1.9 Hz, 1 H, H-2'), 7.88 (br d, *J* = 8.2 Hz, 1 H, H-6'), 7.34 (t, *J* = 8.1 Hz, 1 H, H-5'), 7.30 (s, 1 H, H-8), 7.27 (ddd, *J* = 7.9, 1.4, 0.8 Hz, 1 H, H-4'), 6.72 (dd, *J* = 17.0, 10.2 Hz, 1 H, CH=CH₂), 6.33 (dd, *J* = 17.0, 1.9 Hz, 1 H, CH=CH₂), 5.83 (dd, *J* = 10.2, 1.9 Hz, 1 H, CH=CH₂), 4.27 (t, *J* = 6.3 Hz, 2 H, CH₂CH₂CH₂O), 3.58 (t, *J* = 4.6 Hz, 4 H, morpholino methylene), 2.48 (t, *J* = 7.1 Hz, 2 H, NCH₂CH₂CH₂), 2.38 (m, 4 H, morpholino methylene), 1.99 (quintet, *J* = 6.7 Hz, 2 H, CH₂CH₂CH₂); ¹³C NMR δ 163.49, 156.68, 154.96, 153.92, 149.19, 141.20, 131.58, 130.19, 127.16, 126.95, 125.52, 123.97, 121.03, 120.52, 116.78, 108.80, 107.28,

66.96, 66.14 (×2), 54.54, 53.28 (×2), 25.31. Anal. (C₂₄H₂₆BrN₅O₃·0.5H₂O) C, H, N.

N-[4-[**N**-(3-Bromophenyl)amino]-7-[4-(**N,N**-dimethylamino)butoxy]quinazolin-6-yl]acrylamide (**9**). To a suspension of hexane-washed sodium hydride (11.0 mmol, 440 mg) of a 60% dispersion in mineral oil) in THF (20 mL) was cannulated a solution of 4-(**N,N**-dimethylamino)-1-butanol (8.80 mmol, 1.03 g) in THF (30 mL). The resulting suspension was stirred at 20 °C under N₂ for 2 h and then cannulated into a solution of **39** (0.80 g, 2.20 mmol) in THF (30 mL) under N₂. The dark red solution was heated at reflux overnight, then worked up as above. Chromatography of the crude product on grade III alumina eluting with EtOAc to MeOH/EtOAc (5:95), gave 6-amino-4-[**N**-(3-bromophenyl)amino]-7-[4-(**N,N**-dimethylamino)butoxy]quinazoline (**47c**) (310 mg, 33%): mp (CH₂Cl₂/hexane) 155–156 °C; ¹H NMR [(CD₃)₂SO] δ 9.36 (s, 1 H, NH), 8.39 (s, 1 H, H-2), 8.23 (t, *J* = 1.9 Hz, 1 H, H-2'), 7.86 (br d, *J* = 8.0 Hz, 1 H, H-6'), 7.41 (s, 1 H, H-8), 7.30 (t, *J* = 8.1 Hz, 1 H, H-5'), 7.20 (ddd, *J* = 8.2, 1.9, 0.8 Hz, 1 H, H-4'), 7.09 (s, 1 H, H-5), 5.32 (s, 2 H, NH₂), 4.17 (t, *J* = 6.2 Hz, 2 H, CH₂CH₂CH₂O), 2.47 (t, *J* = 7.3 Hz, 2 H, NCH₂CH₂CH₂CH₂), 2.15 (s, 6 H, N(CH₃)₂), 1.84 (quintet, *J* = 6.4 Hz, 2 H, CH₂CH₂CH₂CH₂), 1.62 (quintet, *J* = 6.9 Hz, 2 H, CH₂CH₂CH₂CH₂). Anal. (C₂₀H₂₄BrN₅O·0.5H₂O) C, H, N.

A solution of **47c** (276 mg, 0.64 mmol), acrylic acid (6 mol equiv, 3.85 mmol, 264 μL), and Et₃N (excess, 1.0 mL) in DMA (10 mL) under N₂ was treated with EDCI·HCl (3 mol equiv, 1.92 mmol, 369 mg). The standard procedure above, followed by chromatography of the product on grade III alumina eluting with EtOAc/hexane (1:1) to MeOH/EtOAc (3:97), gave **9** (98 mg, 32%): mp (CH₂Cl₂/Et₂O) 112–115 °C; ¹H NMR [(CD₃)₂SO] δ 9.77 (s, 1 H, CONH), 9.62 (s, 1 H, NH), 8.88 (s, 1 H, H-5), 8.56 (s, 1 H, H-2), 8.17 (t, *J* = 1.9 Hz, 1 H, H-2'), 7.87 (ddd, *J* = 8.2, 1.9, 1.0 Hz, 1 H, H-6'), 7.34 (t, *J* = 8.2 Hz, 1 H, H-5'), 7.29 (s, 1 H, H-8), 7.27 (ddd, *J* = 8.2, 1.9, 1.0 Hz, 1 H, H-4'), 6.71 (dd, *J* = 17.1, 10.2 Hz, 1 H, CH=CH₂), 6.32 (dd, *J* = 17.1, 1.9 Hz, 1 H, CH=CH₂), 5.82 (dd, *J* = 10.2, 1.9 Hz, 1 H, CH=CH₂), 4.24 (t, *J* = 6.6 Hz, 2 H, CH₂CH₂CH₂CH₂O), 2.27 (t, *J* = 7.2 Hz, 2 H, NCH₂CH₂CH₂CH₂), 2.12 (s, 6 H, N(CH₃)₂), 1.85 (quintet, *J* = 6.9 Hz, 2 H, CH₂CH₂CH₂CH₂), 1.60 (quintet, *J* = 7.4 Hz, 2 H, CH₂CH₂CH₂CH₂). Anal. (C₂₃H₂₆BrN₅O₂·1.25H₂O) C, H, N.

N-[4-[**N**-(3-Bromophenyl)amino]-7-[3-(1*H*-imidazol-1-yl)propoxy]quinazolin-6-yl]acrylamide (**10**). To a suspension of hexane-washed sodium hydride (5.50 mmol, 220 mg) of a 60% dispersion in mineral oil) in THF (20 mL) was cannulated a solution of 3-(1*H*-imidazol-1-yl)-1-propanol (4.84 mmol, 0.61 g) in THF (30 mL). The resulting suspension was stirred at 20 °C under N₂ for 2 h during which time the required sodium alkoxide partially precipitated from solution. Solid **39** (0.80 g, 2.20 mmol) was then added, and the resulting dark red solution was heated at reflux for 24 h, then worked up as above. Chromatography of the product on silica gel, eluting with CH₂Cl₂/EtOAc (1:1) to MeOH/CH₂Cl₂/EtOAc (3:7:10), gave 4-[**N**-(3-bromophenyl)amino]-7-[3-(1*H*-imidazol-1-yl)propoxy]-6-nitroquinazoline (**43d**) (524 mg, 51%): mp (CH₂Cl₂/hexane) 212–215 °C; ¹H NMR [(CD₃)₂SO] δ 10.16 (s, 1 H, NH), 9.30 (s, 1 H, H-5), 8.70 (s, 1 H, H-2), 8.19 (t, *J* = 1.6 Hz, 1 H, H-2'), 7.88 (ddd, *J* = 7.8, 1.5, 1.6 Hz, 1 H, H-6'), 7.63 (s, 1 H, imidazolyl methine), 7.48 (s, 1 H, H-8), 7.39 (t, *J* = 7.9 Hz, 1 H, H-5'), 7.35 (ddd, *J* = 8.0, 1.6, 1.6 Hz, 1 H, H-4'), 7.21 (s, 1 H, imidazolyl methine), 6.90 (s, 1 H, imidazolyl methine), 4.22 (t, *J* = 6.0 Hz, 2 H, CH₂CH₂CH₂O), 4.18 (t, *J* = 6.8 Hz, 2 H, CH₂CH₂CH₂O), 2.26 (quintet, *J* = 6.4 Hz, 2 H, CH₂CH₂CH₂). Anal. (C₂₀H₁₇BrN₆O₃) C, H, N.

Reduction of **43d** (0.51 g, 1.08 mmol) with Fe (0.24 g, 4 mol equiv) in refluxing EtOH/H₂O (2:1, 60 mL) containing glacial AcOH (0.7 mL) as above, followed by chromatography on grade III alumina eluting with MeOH/EtOAc (5:95), gave 6-amino-4-[**N**-(3-bromophenyl)amino]-7-[3-(1*H*-imidazol-1-yl)propoxy]quinazoline (**47d**) (389 mg, 82%): mp (CH₂Cl₂/Et₂O) 178–180 °C; ¹H NMR [(CD₃)₂SO] δ 9.37 (s, 1 H, NH), 8.38 (s, 1 H, H-2), 8.22 (t, *J* = 1.8 Hz, 1 H, H-2'), 7.86 (br d, *J* = 8.1 Hz, 1 H, H-6'), 7.66 (s, 1 H, imidazolyl methine), 7.40 (s, 1 H, H-8), 7.30

(t, $J = 8.1$ Hz, 1 H, H-5'), 7.23 (s, 1 H, imidazolyl methine), 7.21 (br d, $J = 7.7$ Hz, 1 H, H-4'), 7.06 (s, 1 H, H-5), 6.90 (s, 1 H, imidazolyl methine), 5.45 (s, 2 H, NH₂), 4.28 (t, $J = 7.1$ Hz, 2 H, CH₂CH₂CH₂), 4.10 (t, $J = 5.8$ Hz, 2 H, CH₂CH₂CH₂), 2.27 (quintet, $J = 6.5$ Hz, 2 H, CH₂CH₂CH₂). Anal. (C₂₀H₁₉BrN₆O·0.5H₂O) C, H, N.

A stirred solution of 47d (383 mg, 0.87 mmol), acrylic acid (6 mol equiv, 5.23 mmol, 359 μ L), and pyridine (excess, 1.0 mL) in DMA (20 mL) under N₂ was treated with EDCI·HCl (5 mol equiv, 4.36 mmol, 838 mg). The standard procedure above, followed by chromatography on grade III alumina eluting with EtOAc/hexane (1:1) to MeOH/EtOAc (5:95), gave 10 (9 mg, 2%): mp (CH₂Cl₂/Et₂O/hexane) 235–237 °C; ¹H NMR [(CD₃)₂SO] δ 9.79 (s, 1 H, CONH), 9.60 (s, 1 H, NH), 8.88 (s, 1 H, H-5), 8.55 (s, 1 H, H-2), 8.18 (t, $J = 1.9$ Hz, 1 H, H-2'), 7.87 (ddd, $J = 8.1$, 1.9, 1.0 Hz, 1 H, H-6'), 7.64 (s, 1 H, imidazolyl methine), 7.34 (t, $J = 8.1$ Hz, 1 H, H-5'), 7.28 (partially obscured ddd, $J \sim 8$, 1.2, 1.2 Hz, 1 H, H-4'), 7.27 (s, 1 H, H-5), 7.21 (t, $J = 1.3$ Hz, 1 H, imidazolyl methine), 6.89 (br s, 1 H, imidazolyl methine), 6.73 (dd, $J = 17.0$, 10.2 Hz, 1 H, CH=CH₂), 6.34 (dd, $J = 17.0$, 1.8 Hz, 1 H, CH=CH₂), 5.85 (dd, $J = 10.2$, 1.8 Hz, 1 H, CH=CH₂), 4.22 (t, $J = 6.9$ Hz, 2 H, CH₂CH₂CH₂), 4.14 (t, $J = 6.0$ Hz, 2 H, CH₂CH₂CH₂), 2.27 (quintet, $J = 6.4$ Hz, 2 H, CH₂CH₂CH₂). Anal. (C₂₃H₂₁BrN₆O₂·0.75H₂O) C, H, N.

N-[4-[N-(3-Bromophenyl)amino]-7-[3-(N,N-diethylamino)propylthio]quinazolin-6-yl]acrylamide (11). 3-(N,N-Diethylamino)propanethiol hydrochloride (422 mg, 2.20 mmol) was added to a slurry of hexane-washed NaH (60% oil suspension, 320 mg, 8.00 mmol) in DMSO (2 mL) stirred under N₂ at 25 °C. After 20 min, a solution of 39 (726 mg, 2.0 mmol) in DMSO (3 mL) was added, and the dark mixture was heated to 65 °C for 30 min, then poured onto ice-cold saturated NaHCO₃ solution. The precipitate was collected by filtration, rinsed with water, and dried to give 4-[N-(3-bromophenyl)amino]-7-[3-(N,N-diethylamino)propylthio]-6-nitroquinazoline (43e) (940 mg, 100%) as a brown solid, that was used directly; ¹H NMR [(CD₃)₂SO] δ 9.28 (s, 1 H, H-5), 8.34 (s, 1 H, H-2), 7.87 (s, 1 H, H-2'), 7.52 (d, $J = 7.6$ Hz, H-6'), 7.41 (s, 1 H, H-8), 7.21 (t, 1 H, $J = 8.0$ Hz, H-5'), 7.12 (d, 1 H, $J = 8.1$ Hz, H-4'), 3.05 (t, 1 H, $J = 7.2$ Hz, SCH₂), 2.47 (t, 2 H, $J = 7$ Hz, NCH₂), 2.40 (q, 4 H, $J = 7.1$ Hz, NCH₂), 1.72 (quintet, 2 H, $J = 7.1$ Hz, CH₂), 0.90 (t, 6 H, $J = 7.2$ Hz, Me).

Iron powder (446 mg, 8.0 mmol) was added to a vigorously stirred mixture of 43e (940 mg, 2.00 mmol) in refluxing EtOH/water/AcOH (8:4:0.5 mL). After 30 min the reaction mixture was allowed to cool to room temperature, and was then neutralized with concentrated aqueous ammonia, filtered through a pad of Celite, and the residue rinsed with EtOH. The combined filtrates were concentrated to small volume and extracted with EtOAc. The volatiles were removed rigorously under reduced pressure to give 6-amino-4-[N-(3-bromophenyl)amino]-7-[3-(N,N-diethylamino)propylthio]quinazoline (47e) (604 mg, 66%) as a brown solid, that was used directly; ¹H NMR [(CD₃)₂SO] δ 9.48 (s, 1 H, NH), 8.34 (s, 1 H, H-2), 8.16 (s, 1 H, H-2'), 7.81 (d, $J = 7.1$ Hz, H-6'), 7.51 (s, 1 H, H-5), 7.41 (s, 1 H, H-8), 7.26 (t, 1 H, $J = 8.0$ Hz, H-5'), 7.18 (d, 1 H, $J = 7.8$ Hz, H-4'), 5.42 (br s, 2 H, NH₂), 3.03 (t, 1 H, $J = 6.8$ Hz, SCH₂), 2.44 (t, 2 H, $J = 7$ Hz, NCH₂), 2.39 (q, 4 H, $J = 7.1$ Hz, NCH₂), 1.68 (quintet, 2 H, $J = 6.6$ Hz, CH₂), 0.89 (t, 6 H, $J = 6.8$ Hz, CH₃).

A stirred solution of 47e (604 mg, 1.30 mmol) and acrylic acid (0.19 mL, 2.8 mmol) and pyridine (0.22 mL, 2.7 mmol) in DMF (5 mL) was treated with EDCI·HCl (540 mg, 2.8 mmol) under N₂ at 0 °C, and reaction mixture was then stirred at 25 °C for 3 h before being quenched by the addition of water. The mixture was extracted with EtOAc, and the combined extracts were washed with water, saturated brine, dried (MgSO₄) and evaporated under reduced pressure. The residue was flash chromatographed on silica gel, eluting with 2–20% MeOH in CH₂Cl₂, and the appropriate fractions were triturated with Me₂CO to give 11 (116 mg, 17%) as a light brown glass: mp 77–79 °C; ¹H NMR [(CD₃)₂SO] δ 9.88 (s, 1 H, NH), 9.78 (s, 1 H, NH), 8.57 (s, 1 H, H-5), 8.45 (s, 1 H, H-2), 8.16 (t, 1 H, $J =$

1.9 Hz, H-2'), 7.85 (d, $J = 8.8$ Hz, H-6'), 7.56 (s, 1 H, H-8), 7.27 (t, 1 H, $J = 7.9$ Hz, H-5'), 7.21 (d, 1 H, $J = 8.3$ Hz, H-4'), 6.54 (dd, 1 H, $J = 17.5$, 10.5 Hz, CH=CH₂), 6.25 (dd, 1 H, $J = 1.7$, 17.0 Hz, CH=CH₂), 5.77 (d, 1 H, $J = 10.3$ Hz, CH=CH₂), 3.07 (t, 1 H, $J = 7.2$ Hz, SCH₂), 2.47 (t, 2 H, $J = 6.8$ Hz, NCH₂), 2.41 (q, 4 H, $J = 7.1$ Hz, NCH₂), 1.72 (quintet, 2 H, $J = 6.9$ Hz, CH₂), 0.91 (t, 6 H, $J = 7.1$ Hz, CH₃); MS (APCI) 516 (95, ⁸¹BrMH⁺), 514 (100, ⁷⁹BrMH⁺). Anal. (C₂₄H₂₈N₅OBr·H₂O·0.5CH₂Cl₂) C, H, N.

N-[4-[N-(3-Methylphenyl)amino]-7-[3-(4-methyl-1-piperazinyl)propoxy]quinazolin-6-yl]acrylamide (13). A solution of 4-chloro-7-fluoro-6-nitroquinazoline (prepared as described²⁹ from 7-fluoro-6-nitroquinazoline) was dissolved in dry CH₂Cl₂ (50 mL) and added to a stirred solution of 3-methylaniline in *i*-PrOH (30 mL). The reaction mixture was stirred at 20 °C for 30 min and then diluted with hexane (200 mL). The resulting precipitate was collected, washed with hexane and dissolved in MeOH/H₂O (4:1, 150 mL) with gentle warming. The solution was treated with excess Et₃N and diluted with water (400 mL), and the precipitate was filtered, washed with water and dried under reduced pressure to give 7-fluoro-4-[N-(3-methylphenyl)amino]-6-nitroquinazoline (40) (3.01 g, 88%): mp (CH₂Cl₂/hexane) 191–192 °C; ¹H NMR [(CD₃)₂SO] δ 10.38 (s, 1 H, NH), 9.62 (d, $J_{H-F} = 8.1$ Hz, 1 H, H-5), 8.67 (s, 1 H, H-2), 7.80 (d, $J_{H-F} = 12.6$ Hz, 1 H, H-8), 7.63 (br d, $J = 8.2$ Hz, 1 H, H-6'), 7.60 (br s, 1 H, H-2'), 7.31 (t, $J = 7.8$ Hz, 1 H, H-5'), 7.03 (br d, $J = 7.5$ Hz, 1 H, H-4'), 2.35 (s, 3 H, ArCH₃). Anal. (C₁₅H₁₁FN₄O₂) C, H, N.

Sodium metal (0.23 g, 10.1 mmol) was added to a solution of 3-(4-methyl-1-piperazinyl)-1-propanol (1.06 g, 6.71 mmol) in THF (15 mL) under N₂. The resulting suspension was stirred at 20 °C for 2 h and then cannulated into a solution of 40 (0.50 g, 1.68 mmol) in THF (20 mL) under N₂. Standard workup followed by chromatography of the product on alumina, eluting with EtOAc/hexane (1:1) to EtOAc (2:3:5), gave 4-[N-(3-methylphenyl)amino]-7-[3-(4-methyl-1-piperazinyl)propoxy]-6-nitroquinazoline (44a) (0.67 g, 91%): mp (Et₂O/hexane) 155–156 °C; ¹H NMR [(CD₃)₂SO] δ 10.00 (s, 1 H, NH), 9.26 (s, 1 H, H-5), 8.61 (s, 1 H, H-2), 7.64 (br d, $J = 8.4$ Hz, 1 H, H-6'), 7.62 (br s, 1 H, H-2'), 7.43 (s, 1 H, H-8), 7.29 (t, $J = 7.8$ Hz, 1 H, H-5'), 6.99 (br d, $J = 7.4$ Hz, 1 H, H-4'), 4.32 (t, $J = 6.0$ Hz, 2 H, CH₂CH₂CH₂O), 2.44 (t, $J = 7.0$ Hz, 2 H, NCH₂CH₂CH₂), 2.39–2.28 (br s, 8 H, piperazinyl methylene), 2.34 (s, 3 H, CH₃-Ar), 2.14 (s, 3 H, CH₃N), 1.92 (quintet, $J = 6.6$ Hz, 2 H, CH₂CH₂CH₂). Anal. (C₂₃H₂₈N₆O₃) C, H, N.

A solution of 44a (0.61 g, 1.40 mmol) in MeOH/EtOAc (2:1, 50 mL) was hydrogenated (60 psi) over Pd–C for 5 h and then filtered through Celite. The filtrate was concentrated under reduced pressure and chromatographed on grade III alumina, eluting with MeOH/EtOAc (5:95) to give 6-amino-4-[N-(3-methylphenyl)amino]-7-[3-(4-methyl-1-piperazinyl)propoxy]quinazoline (48a) (361 mg), which appeared unstable (rapid discoloration) and was used without further characterization. A stirred solution of 48a (0.36 g, 0.89 mmol), acrylic acid (6 mol equiv, 5.53 mmol, 366 μ L), and Et₃N (excess, 2.0 mL) in DMF (20 mL) under N₂ was treated with EDCI·HCl (3 mol equiv, 2.66 mmol, 511 mg). Standard workup followed by chromatography on grade III alumina, eluting with EtOAc to MeOH/EtOAc (2:98), gave 13 (65 mg, 16%): mp (Et₂O/hexane) 60–66 °C; ¹H NMR [(CD₃)₂SO] δ 9.60 (s, 1 H, exchangeable), 9.59 (s, 1 H, exchangeable), 8.86 (s, 1 H, H-5), 8.48 (s, 1 H, H-2), 7.62 (partially obscured br d, $J = 8.0$ Hz, 1 H, H-6'), 7.62 (br s, 1 H, H-2'), 7.25 (partially obscured t, $J = 8.1$ Hz, 1 H, H-5'), 7.25 (s, 1 H, H-8), 6.92 (br d, $J = 7.5$ Hz, 1 H, H-4'), 6.70 (dd, $J = 17.0$, 10.2 Hz, 1 H, CH=CH₂), 6.31 (dd, $J = 17.0$, 1.8 Hz, 1 H, CH=CH₂), 5.83 (dd, $J = 10.2$, 1.8 Hz, 1 H, CH=CH₂), 4.24 (t, $J = 6.3$ Hz, 2 H, CH₂CH₂CH₂O), 2.47 (t, $J = 7.1$ Hz, 2 H, NCH₂CH₂CH₂), 2.41–2.28 (br s, 8 H, piperazinyl methylene), 2.33 (s, 3 H, CH₃Ar), 2.15 (s, 3 H, CH₃N), 1.97 (quintet, $J = 6.8$ Hz, 2 H, CH₂CH₂CH₂). EI HRMS (M⁺) C₂₆H₃₂N₆O₂: Requires 460.2587. Found: 460.2576.

N-[4-[N-(3-Methylphenyl)amino]-7-[3-(4-morpholinyl)propoxy]quinazolin-6-yl]acrylamide (14). Sodium metal (0.27 g, 11.8 mmol) was added to a solution of 3-(4-morpholi-

nyl)-1-propanol (1.22 g, 8.40 mmol) in THF (40 mL) under N₂. The resulting suspension was stirred at 20 °C for 2 h and then cannulated into a solution of **40** (0.70 g, 2.35 mmol) in THF (30 mL) under N₂. Reaction and workup as above, followed by chromatography on silica gel, eluting with MeOH/CH₂Cl₂/EtOAc (5:45:50) to MeOH/CH₂Cl₂/EtOAc (3:7:10), gave 4-[*N*-(3-methylphenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-nitroquinazoline (**44b**) (0.87 g, 88%): mp (CH₂Cl₂/hexane) 169–170 °C; ¹H NMR [(CD₃)₂SO] δ 10.00 (s, 1 H, NH), 9.26 (s, 1 H, H-5), 8.62 (s, 1 H, H-2), 7.64 (br d, *J* = 8.1 Hz, 1 H, H-6'), 7.62 (br s, 1 H, H-2'), 7.45 (s, 1 H, H-8), 7.29 (t, *J* = 7.8 Hz, 1 H, H-5'), 6.99 (br d, *J* = 7.5 Hz, 1 H, H-4'), 4.34 (t, *J* = 6.1 Hz, 2 H, CH₂CH₂CH₂O), 3.58 (t, *J* = 4.6 Hz, 4 H, morpholino methylene), 2.46 (t, *J* = 7.0 Hz, 2 H, NCH₂CH₂CH₂), 2.38 (br s, 4 H, morpholino methylene), 2.35 (s, 3 H, CH₃Ar), 1.94 (quintet, *J* = 6.6 Hz, 2 H, CH₂CH₂CH₂). Anal. (C₂₂H₂₅N₅O₄) C, H, N.

A solution of **44b** (0.71 g, 1.68 mmol) in MeOH/EtOAc (2:1, 60 mL) was hydrogenated (60 psi) over Pd–C for 6 h and then filtered through Celite and worked up as above to give 6-amino-4-[*N*-(3-methylphenyl)amino]-7-[3-(4-morpholinyl)propoxy]quinazoline (**48b**), which was used without further characterization. A stirred solution of **48b** (0.7 g, 1.8 mmol), acrylic acid (6 mol equiv, 10.8 mmol, 776 μL), and Et₃N (excess, 4.0 mL) in DMF (20 mL) under N₂ was treated with EDCI·HCl (3 mol equiv, 5.38 mmol, 1.03 g). Standard workup and chromatography on silica gel, eluting with CH₂Cl₂/EtOAc (1:1) to MeOH/CH₂Cl₂/EtOAc (3:7:10), gave **14** (175 mg, 22%): mp (EtOAc/Et₂O) 69–72 °C; ¹H NMR [(CD₃)₂SO] δ 9.60 (s, 1 H, exchangeable), 9.59 (s, 1 H, exchangeable), 8.86 (s, 1 H, H-5), 8.48 (s, 1 H, H-2), 7.62 (partially obscured br d, *J* = 8.0 Hz, 1 H, H-6'), 7.61 (br s, 1 H, H-2'), 7.26 (s, 1 H, H-8), 7.25 (t, *J* = 7.8 Hz, 1 H, H-5'), 6.92 (br d, *J* = 7.4 Hz, 1 H, H-4'), 6.70 (dd, *J* = 16.9, 10.2 Hz, 1 H, CH=CH₂), 6.32 (dd, *J* = 16.9, 1.9 Hz, 1 H, CH=CH₂), 5.82 (dd, *J* = 10.2, 1.9 Hz, 1 H, CH=CH₂), 4.26 (t, *J* = 6.3 Hz, 2 H, CH₂CH₂CH₂O), 3.58 (t, *J* = 4.6 Hz, 4 H, morpholino methylene), 2.48 (t, *J* = 7.1 Hz, 2 H, NCH₂CH₂CH₂), 2.38 (m, 4 H, morpholino methylene), 2.33 (s, 3H, CH₃Ar), 1.99 (quintet, *J* = 6.7 Hz, 2 H, CH₂CH₂CH₂). Anal. (C₂₅H₂₉N₅O₃·0.25H₂O) C, H, N.

N-[4-[*N*-(3-bromo-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]quinazolin-6-yl]acrylamide (**16**). Reaction of 4-chloro-7-fluoro-6-nitroquinazoline²⁹ with 3-bromo-4-fluoroaniline, using the procedure previously described for 3-bromoaniline,²⁹ gave 4-[*N*-(3-bromo-4-fluorophenyl)amino]-7-fluoro-6-nitroquinazoline (**41**) (89%): mp (*i*-PrOH) 238–240 °C; ¹H NMR [(CD₃)₂SO] δ 10.51 (s, 1 H, NH), 9.59 (d, *J*_{H-F} = 8.0 Hz, 1 H, H-5), 8.74 (s, 1 H, H-2), 8.24 (dd, *J*_{H-F} = 6.0 Hz, *J* = 2.2 Hz, 1 H, H-2'), 7.87 (m, 1H, H-6'), 7.86 (d, *J*_{H-F} = 12.5 Hz, 1 H, H-8), 7.46 (dd, *J*_{H-F} = 8.8 Hz, *J* = 8.8 Hz, H-5'). Anal. (C₁₄H₇BrF₂N₄O₂) C, H, N.

Treatment of **41** with the sodium salt of 3-(4-morpholinyl)-1-propanol, as described above, gave 4-[*N*-(3-bromo-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-nitroquinazoline (**45b**) (39%): mp (MeOH) 186–188 °C; ¹H NMR [(CD₃)₂SO] δ 10.14 (s, 1 H, NH), 9.21 (s, 1 H, H-5), 8.67 (d, *J* = 1.8 Hz, 1 H, H-2), 8.26 (td, *J*_{H-F} = 6.0 Hz, *J* = 1.8, 1.8 Hz, 1 H, H-2'), 7.89–7.83 (m, 1H, H-6'), 7.48 (s, 1 H, H-8), 7.44 (t, *J* = 8.8 Hz, 1 H, H-5'), 4.35 (t, *J* = 6.1 Hz, 2 H, CH₂CH₂CH₂O), 3.58 (t, *J* = 4.5 Hz, 4 H, morpholino methylene), 2.45 (t, *J* = 6.6 Hz, 2 H, CH₂CH₂CH₂N), 2.38 (m, 4 H, morpholino methylene), 1.95 (quintet, *J* = 6.6 Hz, 2 H, CH₂CH₂CH₂). Anal. (C₂₁H₂₁BrFN₅O₄) C, H, N.

Iron dust reduction of **45b** gave 6-amino-4-[*N*-(3-bromo-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]quinazoline (**49b**) (91%): mp (*i*-Pr₂O/CH₂Cl₂) 149–150 °C; ¹H NMR [(CD₃)₂SO] δ 9.37 (s, 1 H, NH), 8.37 (s, 1 H, H-2), 8.29 (dd, *J*_{H-F} = 6.3 Hz, *J* = 2.5 Hz, 1 H, H-2'), 7.88–7.84 (m, 1 H, H-6'), 7.38 (s, 1 H, H-8), 7.36 (dd, *J*_{H-F} = 8.8 Hz, *J* = 8.8 Hz, 1 H, H-5'), 7.08 (s, 1 H, H-5), 5.34 (s, 2 H, NH₂), 4.20 (t, *J* = 6.2 Hz, 2 H, CH₂CH₂CH₂O), 3.59 (t, *J* = 4.5 Hz, 4 H, morpholino methylene), 2.50 (t, *J* = 7.3 Hz, 2 H, CH₂CH₂CH₂N), 2.40 (m, 4 H, morpholino methylene), 1.99 (quintet, *J* = 6.7 Hz, 2 H, CH₂CH₂CH₂). Anal. (C₂₁H₂₃BrFN₅O₂) C, H, N.

Treatment of **49b** with acrylic acid and EDCI·HCl in DMA, as described above, gave **16** (49%): mp (MeOH) 171–173 °C; ¹H NMR [(CD₃)₂SO] δ 9.80 (s, 1 H, CONH), 9.62 (s, 1 H, NH), 8.87 (s, 1 H, H-5), 8.54 (s, 1 H, H-2), 8.23 (dd, *J*_{H-F} = 5.1 Hz, *J* = 2.6 Hz, 1 H, H-2'), 7.88–7.84 (m, 1 H, H-6'), 7.40 (dd, *J*_{H-F} = 8.8 Hz, *J* = 8.8 Hz, 1 H, H-5'), 7.29 (s, 1 H, H-8), 6.72 (dd, *J* = 17.0, 10.2 Hz, 1 H, CH=CH₂), 6.32 (dd, *J* = 17.0, 1.9 Hz, 1 H, CH=CH₂), 5.83 (dd, *J* = 10.2, 1.9 Hz, 1 H, CH=CH₂), 4.27 (t, *J* = 6.3 Hz, 2 H, CH₂CH₂CH₂O), 3.59 (t, *J* = 4.3 Hz, 4 H, morpholino methylene), 2.49 (t, *J* = 7.3 Hz, 2 H, CH₂CH₂CH₂N), 2.39 (m, 4 H, morpholino methylene), 2.00 (quintet, *J* = 6.7 Hz, 2 H, CH₂CH₂CH₂). Anal. (C₂₄H₂₅BrFN₅O₃·H₂O) C, H, N.

N-[4-[*N*-(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]quinazolin-6-yl]acrylamide (**18**). Reaction of 4-chloro-7-fluoro-6-nitroquinazoline²⁹ with 3-chloro-4-fluoroaniline, as above, gave 4-[*N*-(3-chloro-4-fluorophenyl)amino]-7-fluoro-6-nitroquinazoline (**42**) (72%): mp (*i*-PrOH) 239–240 °C; ¹H NMR [(CD₃)₂SO] δ 10.43 (s, 1 H, NH), 9.53 (d, *J*_{H-F} = 8.0 Hz, 1 H, H-5), 8.70 (s, 1 H, H-2), 8.11 (dd, *J*_{H-F} = 6.7 Hz, *J* = 2.4 Hz, 1 H, H-2'), 7.80 (d, *J*_{H-F} = 12.4 Hz, 1 H, H-8), 7.78 (m, 1H, H-6'), 7.46 (dd, *J*_{H-F} = 9.1 Hz, *J* = 9.1 Hz, H-5'). Anal. (C₁₄H₇ClF₂N₄O₂) C, H, N.

Treatment of **42** with the sodium salt of 3-(4-morpholinyl)-1-propanol, as described above, gave 4-[*N*-(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-nitroquinazoline (**46b**) (58%): mp (MeOH) 194–195 °C; ¹H NMR [(CD₃)₂SO] δ 10.16 (s, 1 H, NH), 9.22 (s, 1 H, H-5), 8.68 (d, *J* = 1.8 Hz, 1 H, H-2), 8.17 (dd, *J*_{H-F} = 6.8 Hz, *J* = 2.5 Hz, 1 H, H-2'), 7.82–7.78 (m, 1H, H-6'), 7.49 (s, 1 H, H-8), 7.47 (dd, *J*_{H-F} = 8.9 Hz, *J* = 8.9 Hz, 1 H, H-5'), 4.35 (t, *J* = 6.1 Hz, 2 H, CH₂CH₂CH₂O), 3.57 (t, *J* = 4.5 Hz, 4 H, morpholino methylene), 2.46 (t, *J* = 7.0 Hz, 2 H, CH₂CH₂CH₂N), 2.37 (m, 4 H, morpholino methylene), 1.94 (quintet, *J* = 6.7 Hz, 2 H, CH₂CH₂CH₂). Anal. (C₂₁H₂₁ClFN₅O₄) C, H, N.

Iron dust reduction of **46b** gave 6-amino-4-[*N*-(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]quinazoline (**50b**) (78%): mp (*i*-Pr₂O/CH₂Cl₂) 166–167 °C; ¹H NMR [(CD₃)₂SO] δ 9.38 (s, 1 H, NH), 8.37 (s, 1 H, H-2), 8.19 (dd, *J*_{H-F} = 6.9 Hz, *J* = 2.7 Hz, 1 H, H-2'), 7.83–7.79 (m, 1 H, H-6'), 7.39 (dd, *J*_{H-F} = 9.1 Hz, *J* = 9.1 Hz, 1 H, H-5'), 7.38 (s, 1 H, H-8), 7.08 (s, 1 H, H-5), 5.36 (s, 2 H, NH₂), 4.20 (t, *J* = 6.2 Hz, 2 H, CH₂CH₂CH₂O), 3.59 (t, *J* = 4.6 Hz, 4 H, morpholino methylene), 2.51 (t, *J* = 7.4 Hz, 2 H, CH₂CH₂CH₂N), 2.40 (m, 4 H, morpholino methylene), 1.99 (quintet, *J* = 6.7 Hz, 2 H, CH₂CH₂CH₂). Anal. (C₂₁H₂₃ClFN₅O₂) C, H, N.

Treatment of **50b** with acrylic acid and EDCI·HCl in DMA, as described above, gave **18** (38%): mp (MeOH) 188–190 °C; ¹H NMR [(CD₃)₂SO] δ 9.80 (s, 1 H, CONH), 9.62 (s, 1 H, NH), 8.87 (s, 1 H, H-5), 8.54 (s, 1 H, H-2), 8.14 (dd, *J*_{H-F} = 6.8 Hz, *J* = 2.6 Hz, 1 H, H-2'), 7.83–7.79 (m, 1 H, H-6'), 7.43 (dd, *J*_{H-F} = 9.2 Hz, *J* = 9.2 Hz, 1 H, H-5'), 7.30 (s, 1 H, H-8), 6.72 (dd, *J* = 17.1, 10.2 Hz, 1 H, CH=CH₂), 6.32 (dd, *J* = 17.1, 1.9 Hz, 1 H, CH=CH₂), 5.83 (dd, *J* = 10.2, 1.9 Hz, 1 H, CH=CH₂), 4.27 (t, *J* = 6.3 Hz, 2 H, CH₂CH₂CH₂O), 3.58 (t, *J* = 4.6 Hz, 4 H, morpholino methylene), 2.48 (t, *J* = 7.1 Hz, 2 H, CH₂CH₂CH₂N), 2.38 (m, 4 H, morpholino methylene), 2.00 (quintet, *J* = 6.7 Hz, 2 H, CH₂CH₂CH₂). Anal. (C₂₄H₂₅ClFN₅O₃·H₂O) C, H, N.

N-[4-[*N*-(3-chloro-4-fluorophenyl)amino]-7-(3,6,9-trioxadecanoxo)quinazolin-6-yl]acrylamide (**19**). A mixture of **42** (673 mg, 2.00 mmol), triethylene glycol monomethyl ether (493 mg, 3.00 mmol) and potassium trimethylsilanolate (770 mg, 6.0 mmol) in DMSO (25 mL) was stirred together under N₂ for 5 h on a 25 °C water bath. The deep crimson mixture was poured onto stirred ice–water (40 mL), and the reddish precipitate was collected by Buchner filtration, rinsed with dilute Na₂CO₃ solution and water (2 × 10 mL), and was dried in a vacuum oven at 60 °C over P₂O₅ to give 4-[*N*-(3-chloro-4-fluorophenyl)amino]-6-nitro-7-(3,6,9-trioxadecanoxo)quinazoline (**46f**) (696 mg, 72%): mp (MeOH) 194–195 °C; ¹H NMR [(CD₃)₂SO] δ 10.16 (br s, 1 H, NH), 9.19 (s, 1 H, H-5), 8.66 (s, 1 H, H-2), 8.15 (dd, 1 H, *J* = 2.3, 6.8 Hz, H-2'), 7.81–7.78 (m, 1 H, H-6'), 7.50 (s, 1 H, H-8), 7.46 (t, 1 H, *J* = 9.1 Hz, H-5'),

4.43 (t, 2 H, $J = 4.2$ Hz, ArOCH_2), 3.82 (t, 2 H, $J = 4.2$ Hz, $\text{ArOCH}_2\text{CH}_2$), 3.62, 3.53, 3.51, 3.41 (dds, 2 H, 2 H, 2 H, 2 H, $J \sim 4$, 6 Hz, OCH_2s), 3.22 (s, 3 H, CH_3).

A solution of 46f (684 mg, 1.42 mmol) in THF (50 mL) was hydrogenated over Raney nickel (0.5 g) at 50.7 psi for 22 h. The mixture was filtered through Celite, and the solution was stripped rigorously to dryness to give 6-amino-4-[*N*-(3-chloro-4-fluorophenyl)amino]-7-(3,6,9-trioxadecanoxo)quinazoline (50f) (654 mg, 95% corrected), contaminated with 17 mol % THF and 9 mol % BHT stabilizer, as a gray-green waxy solid that was used directly: $^1\text{H NMR}$ [$(\text{CD}_3)_2\text{SO}$] δ 9.44 (br s, 1 H, NH), 8.41 (s, 1 H, H-2), 8.23 (dd, 1 H, $J = 2.6$, 6.7 Hz, H-2'), 7.84 (ddd, 1 H, $J = 2.6$, 4.1, 9.1 Hz, H-6'), 7.44 (s, 1 H, H-5), 7.43 (t, 1 H, $J = 9.2$ Hz, H-5'), 7.16 (s, 1 H, H-8), 5.36 (br s, 2 H, NH_2), 4.33 (t, 2 H, $J = 4.5$ Hz, ArOCH_2), 3.91 (t, 2 H, $J = 4.5$ Hz, $\text{ArOCH}_2\text{CH}_2$), 3.68, 3.60 (dds, 2 H, 2 H, $J = 3.6$, 6.4 Hz, OCH_2s), 3.56, 3.46 (dds, 2 H, 2 H, $J = 3.7$, 5.7 Hz, OCH_2s), 3.27 (s, 3 H, CH_3).

Solid 50f was added in one portion to a solution of the anhydride made by adding isobutyl chloroformate (65 mL, 0.5 mmol) dropwise to a stirred solution of acrylic acid (42 mg, 0.58 mmol) and Et_3N (101 mg, 1.0 mmol) in THF (2.5 mL) at 0 °C under N_2 , and keeping for 10 min. After a further 20 min at 0 °C, the reaction mixture was applied directly to preparative TLC plates (silica, two $20 \times 20 \times 0.2$ cm) and eluted once with $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (19:1). The major band (R_f 0.28) was extracted with $\text{MeOH}/\text{CH}_2\text{Cl}_2$, and the solvent was removed under reduced pressure to give 19 (67 mg, 49%): mp 131–132 °C; $^1\text{H NMR}$ [$(\text{CD}_3)_2\text{SO}$] δ 9.83 (br s, 1 H, NH), 9.63 (br s, 1 H, NH), 8.91 (s, 1 H, H-5), 8.54 (s, 1 H, H-2), 8.14 (dd, 1 H, $J = 2.7$, 6.8 Hz, H-2'), 7.80 (ddd, 1 H, $J = 2.7$, 4.4, 9.0 Hz, H-6'), 7.43 (t, 1 H, $J = 9.1$ Hz, H-5'), 7.34 (s, 1 H, H-8), 6.72 (dd, 1 H, $J = 17.0$, 10.4 Hz, $\text{CH}=\text{CH}_2$), 6.32 (dd, 1 H, $J = 1.9$, 17.1 Hz, $\text{CH}=\text{CH}_2$), 5.83 (dd, 1 H, $J = 1.9$, 10.2 Hz, $\text{CH}=\text{CH}_2$), 4.38 (t, 2 H, $J = 4.5$ Hz, Ar OCH_2), 3.89 (t, 2 H, $J = 4.5$ Hz, $\text{ArOCH}_2\text{CH}_2$), 3.64, 3.54 (dds, 2 H, 2 H, $J = 5.4$, 6.3 Hz, OCH_2s), 3.50, 3.41 (dds, 2 H, 2 H, $J = 4.9$, 6.4 Hz, OCH_2s), 3.21 (s, 3 H, OCH_3); MS (APCI) 507 (57, $^{37}\text{CIMH}^+$), 505 (100, $^{35}\text{CIMH}^+$). Anal. ($\text{C}_{24}\text{H}_{26}\text{ClFN}_4\text{O}_5 \cdot 2\text{H}_2\text{O}$) C, H, N.

***N*-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[(1*E*)-4-(4-morpholinyl)-1-butenyl]pyrido[3,2-*d*]pyrimidin-6-yl]-acrylamide (21).** Example of the Method of Scheme 3. A solution of 6-chloro-3-nitropyridine-2-carboxamide (51)⁹ (1.00 g, 4.96 mmol) in EtOH (60 mL) and concentrated ammonia (30 mL) was sealed and heated at 100 °C for 20 h. The mixture was then cooled, concentrated under reduced pressure, and chromatographed on silica gel. Eluants from EtOAc to MeOH/EtOAc (1:4) gave 6-amino-3-nitropyridine-2-carboxamide (52) (658 mg, 73%): mp (EtOAc/MeOH) 219–226 °C dec; $^1\text{H NMR}$ [$(\text{CD}_3)_2\text{SO}$] δ 8.11 (d, $J = 9.2$ Hz, 1 H, H-4), 7.84 (s, 1 H, CONH_2), 7.57 (s, 1 H, NH_2), 7.52 (s, 1 H, CONH_2), 6.50 (d, $J = 9.2$ Hz, 1 H, H-5). Anal. ($\text{C}_6\text{H}_6\text{N}_4\text{O}_3$) C, H, N.

A suspension 52 (0.60 g, 3.29 mmol) in glacial AcOH (70 mL) was heated until homogeneous, then treated with solid KOAc (0.65 g, 6.59 mmol) and allowed to cool to 50 °C. Br₂ (0.34 mL, 6.59 mmol) was then added dropwise, and the reaction was allowed to cool and stirred at room temperature for 1.5 h. The resultant suspension was concentrated under reduced pressure, then diluted with water and basified with solid NaHCO_3 . The aqueous layer was extracted with EtOAc, and this extract was evaporated and the residue chromatographed on silica gel, eluting with EtOAc to MeOH/EtOAc (1:4), to give 6-amino-5-bromo-3-nitropyridine-2-carboxamide (53) (0.72 g, 84%): mp (EtOAc) 250–252 °C; $^1\text{H NMR}$ [$(\text{CD}_3)_2\text{SO}$] δ 8.47 (s, 1 H, H-4), 8.20–7.30 (br s, 2 H, NH_2), 7.89 (s, 1 H, CONH_2), 7.64 (s, 1 H, CONH_2). Anal. ($\text{C}_6\text{H}_5\text{BrN}_4\text{O}_3$) C, H, N, Br.

Iron dust reduction of 53 (14.44 g, 53.3 mmol) as described previously gave crude 5-bromo-3,6-diaminopyridine-2-carboxamide (54). This was not characterized further, but was suspended in triethyl orthoformate (300 mL) and heated at reflux for 3 h. The resulting suspension was concentrated under reduced pressure and diluted with hexane (200 mL). The resulting precipitate was collected, washed with hexane

and dried, then dissolved in 1 N NaOH (600 mL) (heating) and the solution stirred at room temperature for 2 h. Acidification with saturated NH_4Cl precipitated 6-amino-7-bromopyrido[3,2-*d*]pyrimidin-4(3*H*)-one (55) (8.3 g, 62%): mp (AcOH) 300–306 °C dec; $^1\text{H NMR}$ [$(\text{CD}_3)_2\text{SO}$] δ 12.24 (br s, 1 H, NH), 8.12 (s, 1 H, aromatic), 7.88 (s, 1 H, aromatic), 6.91 (br s, 2 H, NH_2). Anal. ($\text{C}_7\text{H}_5\text{BrN}_4\text{O}$) C, H, N.

A suspension of 55 (3.96 g, 16.4 mmol) in 50% HBF_4 (80 mL) was cooled to -10 °C, and NaNO_2 (2.27 g, 32.86 mmol) was added to this suspension in portions over 4 h. The resulting mixture was then kept at -20 °C for 18 h before being warmed to -10 °C and neutralized by the slow addition of solid Na_2CO_3 (keeping the reaction temperature below -5 °C). The precipitate was filtered, washed with water and dried, then suspended in hot DMF and filtered through a pad of Celite which was washed with further hot DMF. The combined filtrates were evaporated to dryness under reduced pressure and chromatographed on silica gel. Gradient elution from $\text{MeOH}/\text{CH}_2\text{Cl}_2$ (1:9) to $\text{MeOH}/\text{CH}_2\text{Cl}_2$ (1:4) gave 7-bromo-6-fluoropyrido[3,2-*d*]pyrimidin-4(3*H*)-one (56) (2.15 g, 54%): mp ($\text{MeOH}/\text{H}_2\text{O}$) 301–305 °C dec; $^1\text{H NMR}$ [$(\text{CD}_3)_2\text{SO}$] δ 12.81 (br s, 1 H, NH), 8.69 (d, $J_{\text{H-F}} = 8.1$ Hz, 1 H, H-8), 8.21 (s, 1 H, H-2). Anal. ($\text{C}_7\text{H}_3\text{BrFN}_3\text{O}$) C, H, N, F.

A suspension of 56 (70 mg, 0.29 mmol) in POCl_3 (15 mL) was heated at reflux for 20 min (when all material had dissolved), and then for a further 1.5 h. Excess POCl_3 was removed under reduced pressure, and the residue was dissolved in CH_2Cl_2 , washed several times with saturated NaHCO_3 and brine and dried (Na_2SO_4). Evaporation under reduced pressure gave crude 7-bromo-4-chloro-6-fluoropyrido[3,2-*d*]pyrimidine, which was dissolved in *i*-PrOH (15 mL) and added to a solution of 3-chloro-4-fluoroaniline (84 mg, 0.57 mmol) in *i*-PrOH (20 mL) containing 1 drop of concentrated HCl. The resulting solution was heated under reflux for 5 min, and then at 60 °C for 30 min. The volume was then reduced to approximately 10 mL by evaporation under reduced pressure, and saturated aqueous NaHCO_3 was added. The resulting precipitate was collected by filtration, washed with water and dried under vacuum to give 7-bromo-4-[*N*-(3-chloro-4-fluorophenyl)amino]-6-fluoropyrido[3,2-*d*]pyrimidine (57) (96 mg, 90%): mp (EtOAc) 249–251 °C; $^1\text{H NMR}$ [$(\text{CD}_3)_2\text{SO}$] δ 10.37 (s, 1 H, NH), 8.84 (d, $J_{\text{H-F}} = 8.3$ Hz, 1 H, H-8), 8.72 (d, $J = 1.9$ Hz, 1 H, H-2), 8.32 (m, 1 H, H-2'), 7.98 (m, 1 H, H-6'), 7.46 (dd, $J_{\text{H-F}} = 9.1$ Hz, $J = 9.1$ Hz, 1 H, H-5'). Anal. ($\text{C}_{13}\text{H}_6\text{BrClF}_2\text{N}_4$) C, H, N.

A stirred solution of 3-buten-1-ol (6.00 g, 85.6 mmol) in CH_2Cl_2 (200 mL) at 0 °C was treated with Et_3N (256.8 mmol, 35.8 mL) followed by MsCl (111.3 mmol, 8.6 mL) dropwise. After stirring the reaction mixture for 30 min, morpholine (119.8 mmol, 10.5 mL) was added and the reaction mixture was allowed to warm to room temperature for 16 h. Further morpholine (10.5 mL) was then added, and the reaction was heated at reflux for 8 h. The solution was washed with saturated aqueous NaHCO_3 and brine, dried (Na_2SO_4) and concentrated under reduced pressure. The resulting crude oil was filtered through a short column of silica gel, eluting with EtOAc/hexane (1:1), and the eluate, after the removal of solvent, was distilled to give 4-(3-butenyl)morpholine (58) (6.47 g, 54%) as a colorless oil; $^1\text{H NMR}$ (CDCl_3) δ 3.72 (t, $J = 4.7$ Hz, 4 H, morpholino methylene), 2.59 (t, $J = 7.8$ Hz, 2 H, H-4), 2.49 (t, $J = 4.7$ Hz, 4 H, morpholino methylene), 2.38 (m, 2 H, H-3), 1.98 (s, 1 H, H-1).

To neat degassed 58 (3.64 g, 26.2 mmol) under N_2 was added AIBN (catalytic, 50 mg) followed by tributyltin hydride (26.2 mmol, 7.04 mL). The reaction mixture was heated to 90 °C with adequate venting (vigorous initial reaction) and kept at 90 °C for a further 16 h. The cooled mixture was diluted with hexane and chromatographed directly on silica gel, using gradient elution from hexane to EtOAc/hexane (2:3), to give 4-[(3*E*)-4-(tributylstannyl)-3-butenyl]morpholine (59) (7.76 g, 69%) as a colorless oil: $^1\text{H NMR}$ (CDCl_3) δ 5.94 (m, 2 H, $\text{CH}=\text{CH}$), 3.71 (t, $J = 4.6$ Hz, 4 H, morpholino methylene), 2.46 (t, $J = 4.6$ Hz, 4 H, morpholino methylene), 2.42 (partially obscured, m, 2 H, $\text{NCH}_2\text{CH}_2\text{CH}$), 2.33 (m, 2 H, $\text{NCH}_2\text{CH}_2\text{CH}$),

1.48 (m, 6 H, $\text{Sn}(\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3)_3$), 1.30 (m, 6 H, $\text{Sn}(\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3)_3$), 0.89m (partially obscured t, $J = 7.2$ Hz, 9 H, $\text{Sn}(\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3)_3$), 0.87 (partially obscured m, 6 H, $\text{Sn}(\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3)_3$); ^{13}C NMR δ 146.6, 129.2, 67.0 ($\times 2$), 58.4, 53.7 ($\times 2$), 35.2, 29.1 ($\times 3$), 13.7 ($\times 3$), 9.4 ($\times 3$).

The above stannane **59** (19.29 mmol, 8.30 g) was added to a degassed solution of **57** (4.78 g, 12.86 mmol) and catalytic tetrakis(triphenylphosphine)palladium(0) (1.29 mmol, 1.49 g), in DMF (100 mL) under nitrogen. The reaction mixture was heated to 100 °C for 75 min (reaction complete by TLC), then diluted with water and extracted with EtOAc. The combined organic extracts were washed with water and dried (Na_2SO_4), then evaporated under reduced pressure. Chromatography on silica gel, eluting with EtOAc to MeOH/EtOAc (1:4), gave 4-[*N*-(3-chloro-4-fluorophenyl)amino]-6-fluoro-7-[(1*E*)-4-(4-morpholinyl)-1-butenyl]pyrido[3,2-*d*]pyrimidine (**60**) (3.98 g, 72%): mp (Et₂O/hexane) 189–190 °C; ^1H NMR [(CD₃)₂SO] δ 10.21 (s, 1 H, NH), 8.70 (s, 1 H, H-2), 8.48 (d, $J_{\text{H-F}} = 9.2$ Hz, 1 H, H-8), 8.35 (m, 1 H, H-2'), 7.99 (m, 1 H, H-6'), 7.45 (dd, $J_{\text{H-F}} = 9.1$ Hz, $J = 9.1$ Hz, 1 H, H-5'), 6.85 (m, 1 H, CH₂CH=CH), 6.66 (d, $J = 16.0$ Hz, 1 H, CH₂CH=CH), 3.59 (t, $J = 4.5$ Hz, 4 H, morpholino methylene), 2.50 (br s, 4 H, CH₂CH₂CH=CH), 2.42 (t, $J = 4.5$ Hz, 4 H, morpholino methylene). Anal. (C₂₁H₂₀ClF₂N₅O) C, H, N.

A suspension of **60** (325 mg, 0.753 mmol) in *i*-PrOH (60 mL) was saturated with NH₃(g), then sealed in a pressure vessel and heated at 100 °C for 20 h. The resulting solution was cooled and evaporated to dryness under reduced pressure, then chromatographed on silica gel, eluting with MeOH/EtOAc (1:8), to give 6-amino-4-[*N*-(3-chloro-4-fluorophenyl)amino]-7-[(1*E*)-4-(4-morpholinyl)-1-butenyl]pyrido[3,2-*d*]pyrimidine (**61**) (316 mg, 98%): mp (EtOAc) 157–158 °C; ^1H NMR [(CD₃)₂SO] δ 9.36 (s, 1 H, NH), 8.44 (s, 1 H, H-2), 8.41 (m, 1 H, H-2'), 7.88 (s, 1 H, H-8), 7.86 (m, 1 H, H-6'), 7.43 (dd, $J_{\text{H-F}} = 9.1$ Hz, $J = 9.1$ Hz, 1 H, H-5'), 6.69 (partially obscured d, $J = 15.5$ Hz, 1 H, CH₂CH=CH), 6.67 (s, 2 H, NH₂), 6.49 (dt, $J = 15.5$, 6.7 Hz, 1 H, CH₂CH=CH), 3.59 (t, $J = 4.6$ Hz, 4 H, morpholino methylene), 2.48–2.43 (m, 4 H, CH₂CH₂CH=CH), 2.42 (br t, $J = 4.6$ Hz, 4 H, morpholino methylene). Anal. (C₂₁H₂₂ClFN₆O) C, H, N.

Acrylic acid (36.0 mmol, 2.54 mL) was added to a solution of Et₃N (52.9 mmol, 7.44 mL) in dry THF (100 mL) at 0 °C under N₂. This mixture was then treated dropwise with 2,4,6-trichlorobenzoyl chloride (31.7 mmol, 4.90 mL), and the resulting suspension was stirred for 15 min. A solution of **61** (907 mg, 2.11 mmol) and DMAP (0.42 mmol, 51 mg) in dry THF (60 mL) under N₂ was then added via cannula. The resulting mixture was stirred at 0 °C for a further 15 min before being warmed to room temperature. After 2 h (when TLC showed the reaction was complete), the mixture was diluted with water and extracted with EtOAc. The combined organic extracts were washed with water and dried (Na_2SO_4), then concentrated under reduced pressure and filtered through a plug of alumina in EtOAc to remove yellow polymeric baseline material. The crude residue was then stirred overnight in aqueous MeOH (10%, 80 mL) to hydrolyze any bisacyl material. The solvent was then partially removed under reduced pressure, and the residue was diluted with saturated NaHCO₃ and extracted with CH₂Cl₂. The combined organic extracts were washed with brine, dried (Na_2SO_4) and evaporated under reduced pressure. The residue was chromatographed on silica gel, eluting with EtOAc/DCM/MeOH (60:25:15), to give **21** (340 mg, 33%): mp (EtOAc/MeOH/Et₂O) 190–193 °C; ^1H NMR [(CD₃)₂SO] δ 10.65 (s, 1 H, CONH), 10.00 (s, 1 H, NH), 8.69 (s, 1 H, H-2), 8.39 (m, 1 H, H-2'), 8.37 (s, 1 H, H-8), 7.97 (m, 1 H, H-6'), 7.45 (dd, $J_{\text{H-F}} = 9.1$ Hz, $J = 9.1$ Hz, 1 H, H-5'), 6.67 (dt, $J = 15.9$, 6.5 Hz, 1 H, CH₂CH=CH), 6.57 (dd, $J = 17.1$, 10.2 Hz, 1 H, COCH=CH₂), 6.52 (d, $J = 15.9$ Hz, 1 H, CH₂CH=CH), 6.34 (dd, $J = 17.1$, 1.7 Hz, 1 H, COCH=CH₂), 5.86 (dd, $J = 10.2$, 1.7 Hz, 1 H, COCH=CH₂), 3.58 (t, $J = 4.6$ Hz, 4 H, morpholino methylene), 2.44–2.37 (m, 8 H, CH₂CH₂CH=CH, morpholino methylene). HRMS (FAB) $M + 1$ Required for C₂₄H₂₄ClF₂N₆O₂: 483.17114. Found: 483.17136.

N-[4-[*N*-(3-Chloro-4-fluorophenyl)amino]-7-[4-(4-morpholinyl)butyl]pyrido[3,2-*d*]pyrimidin-6-yl]acrylamide (**22**). A solution of **60** (3.60 g, 8.34 mmol) in THF/MeOH (2:1, 400 mL) was hydrogenated over PtO₂·xH₂O at 60 psi for 18 h before being filtered through Celite and concentrated under reduced pressure. Chromatography on a short column of alumina, eluting with MeOH/EtOAc (1:9), gave 4-[*N*-(3-chloro-4-fluorophenyl)amino]-6-fluoro-7-[4-(4-morpholinyl)butyl]pyrido[3,2-*d*]pyrimidine (**62**) (3.40 g, 94%): mp (EtOAc) 147–148 °C; ^1H NMR [(CD₃)₂SO] δ 10.21 (s, 1 H, NH), 8.70 (d, $J = 1.6$ Hz, 1 H, H-2), 8.36 (m, 1 H, H-2'), 8.28 (d, $J_{\text{H-F}} = 9.1$ Hz, 1 H, H-8), 7.99 (m, 1 H, H-6'), 7.45 (dd, $J_{\text{H-F}} = 9.1$ Hz, $J = 9.1$ Hz, 1 H, H-5'), 3.55 (t, $J = 4.6$ Hz, 4 H, morpholino methylene), 2.84 (t, $J = 7.5$ Hz, 2 H, CH₂Ar), 2.31 (m, 6 H, morpholino methylene, NCH₂CH₂CH₂CH₂Ar), 1.71 (quintet, $J = 7.5$ Hz, 2 H, NCH₂CH₂CH₂CH₂Ar), 1.50 (quintet, $J = 7.5$ Hz, 2 H, NCH₂CH₂CH₂CH₂Ar). Anal. (C₂₁H₂₂ClF₂N₅O) C, H, N.

A suspension of **62** (1.83 g, 4.22 mmol) in *i*-PrOH (240 mL) was treated with NH₃(g) as above to give 6-amino-4-[*N*-(3-chloro-4-fluorophenyl)amino]-7-[4-(4-morpholinyl)butyl]pyrido[3,2-*d*]pyrimidine (**63**) (1.65 g, 91%): mp (MeOH) 182–183 °C; ^1H NMR [(CD₃)₂SO] δ 9.33 (s, 1 H, NH), 8.44 (s, 1 H, H-2), 8.41 (ddd, $J_{\text{H-F}} = 6.9$ Hz, $J = 2.6$, 2.6 Hz, 1 H, H-2'), 7.85 (m, 1 H, H-6'), 7.67 (s, 1 H, H-8), 7.43 (dd, $J_{\text{H-F}} = 9.1$ Hz, $J = 9.1$ Hz, 1 H, H-5'), 6.64 (s, 2 H, NH₂), 3.57 (t, $J = 4.6$ Hz, 4 H, morpholino methylene), 2.64 (t, $J = 7.4$ Hz, 2 H, CH₂Ar), 2.33 (m, 6 H, morpholino methylene, NCH₂CH₂CH₂CH₂Ar), 1.64 (quintet, $J = 7.4$ Hz, 2 H, NCH₂CH₂CH₂CH₂Ar), 1.53 (quintet, $J = 7.4$ Hz, 2 H, NCH₂CH₂CH₂CH₂Ar). Anal. (C₂₁H₂₄ClFN₆O) C, H, N.

To a solution of **63** (1.65 g, 3.82 mmol) in DMA/THF (1:1, 100 mL) at 0 °C were added 1-hydroxybenzotriazole (3.82 mmol, 516 mg), triethylamine (57.3 mmol, 4.1 mL), acrylic acid (22.9 mmol, 1.58 mL) and EDCI·HCl (22.9 mmol, 4.40 g). The reaction mixture was stirred at 0 °C under N₂ for 30 min, then allowed to warm to room temperature. Additional acrylic acid (260 μL) and EDCI·HCl (730 mg) were added to the suspension twice weekly. After 6 weeks (despite considerable starting material remaining), the reaction mixture was diluted with water, basified with saturated aqueous NaHCO₃, and extracted with EtOAc. The combined organic extracts were washed with brine and dried (Na_2SO_4), then evaporated under reduced pressure. Chromatography (2 \times) on silica gel, eluting with EtOAc/CH₂Cl₂/MeOH (7:2:1) gave a fraction (approximately 400 mg) enriched in the desired product. Reverse-phase preparative layer chromatography of this, eluting with MeOH/H₂O/cNH₃ (93:5:2) (running each plate 3 \times) gave, at highest R_f , **22** (155 mg, 8%, 28% based on recovered starting material): mp (EtOAc) 180–182 °C; ^1H NMR [(CD₃)₂SO] δ 10.57 (s, 1 H, CONH), 10.00 (s, 1 H, NH), 8.69 (d, $J = 1.6$ Hz, 1 H, H-2), 8.37 (m, 1 H, H-2'), 8.13 (s, 1 H, H-8), 7.96 (m, 1 H, H-6'), 7.45 (dd, $J_{\text{H-F}} = 9.1$ Hz, $J = 9.1$ Hz, 1 H, H-5'), 6.56 (dd, $J = 17.0$, 10.2 Hz, 1 H, CH=CH₂), 6.33 (dd, $J = 17.0$, 1.8 Hz, 1 H, CH=CH₂), 5.85 (dd, $J = 10.2$, 1.8 Hz, 1 H, CH=CH₂), 3.54 (t, $J = 4.6$ Hz, 4 H, morpholino methylene), 2.78 (t, $J = 7.5$ Hz, 2 H, CH₂Ar), 2.27 (m, 6 H, morpholino methylene, NCH₂CH₂CH₂CH₂Ar), 1.66 (quintet, $J = 7.5$ Hz, 2 H, NCH₂CH₂CH₂CH₂Ar), 1.44 (quintet, $J = 7.5$ Hz, 2 H, NCH₂CH₂CH₂CH₂Ar). Anal. (C₂₄H₂₆ClFN₆O₂·0.5H₂O) C, H, N.

Starting material **63** (1.16 g combined weight from column and preparative layer chromatography, 70%) was also recovered: ^1H NMR identical to an authentic sample.

N-[4-[*N*-(3-Chloro-4-fluorophenyl)amino]-7-methoxy-pyrido[3,2-*d*]pyrimidin-6-yl]acrylamide (**23**). Example of the Method of Scheme 4. A solution of 2-bromo-5-methoxy-6-(methylthio)-3-nitropyridine¹⁸ (**64**) (7.70 g, 27.6 mmol) in NMP (50 mL) was added to a solution of CuCN (4.94 g, 55.2 mmol) in NMP (200 mL) at 170 °C. The resultant mixture was heated at 170 °C for 10 min, then cooled and poured into ice water (2 L). The resulting precipitate was collected by filtration, washed with water, suspended in boiling EtOAc (400 mL) and filtered hot through a pad of Celite. The Celite was washed with EtOAc, and the combined filtrates were dried (Na_2SO_4) and evaporated to give 2-cyano-5-methoxy-6-(methylthio)-3-

nitropyridine (**65**) (5.90 g, 95%): mp (EtOAc/hexane) 168–170 °C; ¹H NMR [(CD₃)₂SO] δ 8.02 (s, 1 H, H-4), 4.10 (s, 3 H, OCH₃), 2.58 (s, 3 H, SCH₃). Anal. (C₈H₇N₃O₃S) C, H, N.

A solution of **65** (5.19 g, 23.0 mmol) in 90% H₂SO₄ (80 mL) was warmed at 50 °C for 1.5 h before being poured onto ice (1 L) and extracted with EtOAc. The combined organic extracts were washed with saturated aqueous NaHCO₃ and brine, then dried (Na₂SO₄). Evaporation gave a residue that was chromatographed on silica gel, eluting with EtOAc/hexane (1:1), to give 5-methoxy-6-(methylthio)-3-nitropyridine-2-carboxamide (**66**) (0.80 g, 14%): mp (Et₂O/hexane) 215–217 °C; ¹H NMR [(CD₃)₂SO] δ 8.04 (s, 1 H, CONH₂), 7.84 (partially obscured s, 1 H, CONH₂), 7.83 (s, 1 H, H-4), 3.99 (s, 3 H, OCH₃), 2.58 (s, 3 H, SCH₃). Anal. (C₈H₇N₃O₅S) C, H, N.

A solution of **66** (0.57 g, 2.34 mmol) in EtOAc/MeOH (1:1, 150 mL) was hydrogenated over Pd–C at 60 psi for 16 h, before fresh catalyst was added and the hydrogenation continued for a further 7 h. The solution was then filtered through Celite and evaporated to give crude 3-amino-5-methoxy-6-(methylthio)pyridine-2-carboxamide (**67**), which was suspended in neat triethyl orthoformate (30 mL) and heated under reflux for 8 h. The reaction mixture was concentrated under reduced pressure, hexane was added, and the resultant precipitate was collected, washed with hexane and dried to give 7-methoxy-6-(methylthio)pyrido[3,2-*d*]pyrimidin-4(3*H*)-one (**68**) (422 mg, 81%): mp (MeOH) 279–281 °C; ¹H NMR [(CD₃)₂SO] δ 12.44 (s, 1 H, NH), 8.08 (s, 1 H, H-2), 7.37 (s, 1 H, H-8), 4.00 (s, 3 H, OCH₃), 2.55 (s, 3 H, SCH₃). Anal. (C₉H₉N₃O₂S) C, H, N.

Iron dust reduction of **65** (22.0 g, 97.7 mmol) as above gave crude 3-amino-2-cyano-5-methoxy-6-(methylthio)pyridine (**69**) which was filtered through a short column of silica gel, eluting with MeOH/EtOAc (1:9) to remove baseline impurities. The amine **69** was then added in portions over 1 h to a refluxing solution of 88% HCO₂H (200 mL) and concentrated H₂SO₄ (3.6 mL). The reaction was refluxed for 16 h, then cooled to room temperature and poured into ice water (2 L). The precipitate was filtered, washed with water, CH₂Cl₂/Et₂O (1:1) and then Et₂O and dried to give **68** (17.98 g, 82%): ¹H NMR identical to an authentic sample.

Activation of **68** (0.52 g, 2.33 mmol) in POCl₃ (20 mL) and subsequent reaction with 3-chloro-4-fluoroaniline (0.68 g, 4.66 mmol) as above gave, after chromatography on silica gel, eluting with EtOAc/CH₂Cl₂ (1:1), 4-[*N*-(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-(methylthio)pyrido[3,2-*d*]pyrimidine (**70a**) (0.63 g, 77%): mp (CH₂Cl₂/Et₂O) 234–236 °C; ¹H NMR [(CD₃)₂SO] δ 9.54 (s, 1 H, NH), 8.59 (s, 1 H, H-2), 8.26 (m, 1 H, H-2'), 7.93 (m, 1 H, H-6'), 7.47 (m, 2 H, H-8, H-5'), 4.05 (s, 3 H, OCH₃), 2.75 (s, 3 H, SCH₃). Anal. (C₁₅H₁₂ClF₂N₄OS) C, H, N.

A solution of **70a** (0.62 g, 1.77 mmol) in CH₂Cl₂ (350 mL) was treated with *m*-CPBA (1.94 mmol, 0.45 g of 75%) for 1 h at room temperature, then washed with saturated aqueous NaHCO₃ and brine, dried (Na₂SO₄) and concentrated under reduced pressure. Addition of hexane to the concentrate gave a precipitate that was collected and washed with hexane to give 4-[*N*-(3-chloro-4-fluorophenyl)amino]-6-(methanesulfinyl)-7-methoxypyrido[3,2-*d*]pyrimidine (**71a**) (0.63 g, 97%): mp (CH₂Cl₂/Et₂O) 222–224 °C; ¹H NMR [(CD₃)₂SO] δ 10.17 (s, 1 H, NH), 8.69 (s, 1 H, H-2), 8.28 (dd, *J*_{H-F} = 6.8 Hz, *J* = 2.5 Hz, 1 H, H-2'), 7.92 (m, 1 H, H-6'), 7.83 (s, 1 H, H-8), 7.48 (dd, *J*_{H-F} = 9.0 Hz, *J* = 9.0 Hz, 1 H, H-5'), 4.09 (s, 3 H, OCH₃), 3.06 (s, 3 H, S(O)CH₃). Anal. (C₁₅H₁₂ClF₂N₄O₂S) C, H, N.

A suspension of **71a** (0.63 g, 1.72 mmol) in *i*-PrOH (100 mL) was reacted with NH₃(g) as above to give, after column chromatography on silica gel and elution with CH₂Cl₂/EtOAc (1:1) to MeOH/CH₂Cl₂/EtOAc (2:48:50), 6-amino-4-[*N*-(3-chloro-4-fluorophenyl)amino]-7-methoxypyrido[3,2-*d*]pyrimidine (**72a**) (0.23 g, 42%): mp (CH₂Cl₂/Et₂O) 258–260 °C; ¹H NMR [(CD₃)₂SO] δ 9.23 (s, 1 H, NH), 8.44 (s, 1 H, H-2), 8.39 (m, 1 H, H-2'), 7.84 (m, 1 H, H-6'), 7.41 (dd, *J*_{H-F} = 9.1 Hz, *J* = 9.1 Hz, 1 H, H-5'), 7.28 (s, 1 H, H-8), 6.68 (s, 2 H, NH₂), 3.99 (s, 3 H, OCH₃). Anal. (C₁₄H₁₁ClF₂N₅O) C, H, N.

A solution of **72a** (0.25 g, 0.782 mmol) in THF was reacted with the mixed anhydride of 2,4,6-trichlorobenzoyl chloride

and acrylic acid as described above. Chromatography on silica gel, with gradient elution from CH₂Cl₂/EtOAc (1:1) to MeOH/CH₂Cl₂/EtOAc (1:4:5), gave **23** (123 mg, 42%): mp (EtOAc/Et₂O) 226–228 °C; ¹H NMR [(CD₃)₂SO] δ 10.39 (s, 1 H, CONH), 9.69 (s, 1 H, NH), 8.65 (s, 1 H, H-2), 8.36 (m, 1 H, H-2'), 7.89 (m, 1 H, H-6'), 7.69 (s, 1 H, H-8), 7.45 (dd, *J*_{H-F} = 9.0 Hz, *J* = 9.0 Hz, 1 H, H-5'), 6.66 (dd, *J* = 17.1, 10.2 Hz, 1 H, C#C=CH₂), 6.33 (dd, *J* = 17.1, 1.9 Hz, 1 H, C#C=CH₂), 5.84 (dd, *J* = 10.2, 1.9 Hz, 1 H, C#C=CH₂), 4.04 (s, 3 H, OCH₃). Anal. (C₁₇H₁₃ClF₂N₅O₂) C, H, N.

N-[4-[*N*-(3-chloro-4-fluorophenyl)amino]-7-(2-methoxyethoxy)pyrido[3,2-*d*]pyrimidin-6-yl]acrylamide (**24**). Example of the Method of Scheme 5. Anhydrous pyridine hydrochloride was prepared by adding concentrated HCl (37%, 148 mL) to a solution of pyridine (150 mL) in CH₂Cl₂ (250 mL) at 0 °C, followed by concentration to dryness under reduced pressure. This was then heated to 200 °C under N₂, and solid **70a** (10.5 g, 29.9 mmol) was then added. Once the solid had gone into solution (approximately 3 min) the reaction was heated at 200–210 °C for a further 5 min before being cooled to approximately 100 °C and diluted with water (500 mL). The resulting precipitate was collected by filtration and washed with water, then dissolved in DMSO (150 mL) (heating to 90 °C) and treated with activated charcoal for 10 min. The solution was filtered through Celite, the Celite was washed with DMSO (50 mL), and the combined filtrates were diluted with water (300 mL). The precipitate was collected, washed with water and Et₂O and dried to give 4-[*N*-(3-chloro-4-fluorophenyl)amino]-7-hydroxy-6-(methylthio)pyrido[3,2-*d*]pyrimidine (**73**) (8.05 g, 80%): mp (MeOH) 290–300 °C dec; ¹H NMR [(CD₃)₂SO] δ 11.82 (br s, 1 H, OH), 9.51 (s, 1 H, NH), 8.53 (s, 1 H, H-2), 8.26 (m, 1 H, H-2'), 7.92 (m, 1 H, H-6'), 7.46 (dd, *J*_{H-F} = 9.1 Hz, *J* = 9.1 Hz, 1 H, H-5'), 7.18 (s, 1 H, H-8), 2.72 (s, 3 H, SCH₃). Anal. (C₁₄H₁₀ClF₂N₄OS) C, H, N.

A suspension of **73** (400 mg, 1.19 mmol) in DMF (15 mL) was heated briefly to 100 °C, and the resultant solution was cooled to 60 °C and treated successively with K₂CO₃ (1.15 g, 8.32 mmol) and 2-bromoethyl methyl ether (558 μL, 5.94 mmol). The resulting mixture was heated at 60 °C for 2 h, then diluted with water and extracted with EtOAc. The combined organic extracts were washed with brine, dried (Na₂SO₄) and evaporated, and the residue was chromatographed on silica gel, eluting with EtOAc/CH₂Cl₂ (1:1) to EtOAc/CH₂Cl₂/MeOH (10:9:1), to give 4-[*N*-(3-chloro-4-fluorophenyl)amino]-7-(2-methoxyethoxy)-6-(methylthio)pyrido[3,2-*d*]pyrimidine (**70b**) (342 mg, 73%): mp (MeOH/Et₂O) 169–171 °C; ¹H NMR [(CD₃)₂SO] δ 9.53 (s, 1 H, NH), 8.58 (s, 1 H, H-2), 8.27 (m, 1 H, H-2'), 7.93 (m, 1 H, H-6'), 7.49 (s, 1 H, H-8), 7.46 (partially obscured dd, *J*_{H-F} = 9.1 Hz, *J* = 9.1 Hz, 1 H, H-5'), 4.40 (t, *J* = 4.3 Hz, 2 H, CH₂CH₂OCH₃), 3.76 (t, *J* = 4.3 Hz, 2 H, CH₂CH₂OCH₃), 3.37 (s, 3 H, OCH₃), 2.74 (s, 3 H, SCH₃). Anal. (C₁₇H₁₆ClF₂N₄O₂S) C, H, N.

A solution of **70b** (242 mg, 0.613 mmol) in CH₂Cl₂ (70 mL) was oxidized with *m*-CPBA as above to give 4-[*N*-(3-chloro-4-fluorophenyl)amino]-6-(methanesulfinyl)-7-(2-methoxyethoxy)pyrido[3,2-*d*]pyrimidine (**71b**) (146 mg, 58%): mp (MeOH/EtOAc) 237–240 °C; ¹H NMR [(CD₃)₂SO] δ 10.50 (s, 1 H, NH), 8.70 (s, 1 H, H-2), 8.32 (dd, *J*_{H-F} = 6.9 Hz, *J* = 2.7 Hz, 1 H, H-2'), 7.95 (m, 1 H, H-6'), 7.85 (s, 1 H, H-8), 7.48 (dd, *J*_{H-F} = 9.1 Hz, *J* = 9.1 Hz, 1 H, H-5'), 4.48 (m, 2 H, CH₂CH₂OCH₃), 3.76 (t, *J* = 4.3 Hz, 2 H, CH₂CH₂OCH₃), 3.37 (s, 3 H, OCH₃), 3.02 (s, 3 H, S(O)CH₃). Anal. (C₁₇H₁₆ClF₂N₄O₃S·0.5H₂O) C, H, N.

A suspension of **71b** (0.30 g, 0.73 mmol) in *i*-PrOH (80 mL) was reacted with NH₃(g) as above to give 6-amino-4-[*N*-(3-chloro-4-fluorophenyl)amino]-7-(2-methoxyethoxy)pyrido[3,2-*d*]pyrimidine (**72b**) (251 mg, 94%): mp (EtOAc/Et₂O) 195–197 °C; ¹H NMR [(CD₃)₂SO] δ 9.24 (s, 1 H, NH), 8.44 (s, 1 H, H-2), 8.40 (dd, *J*_{H-F} = 6.9 Hz, *J* = 2.7 Hz, 1 H, H-2'), 7.85 (m, 1 H, H-6'), 7.41 (dd, *J*_{H-F} = 9.1 Hz, *J* = 9.1 Hz, 1 H, H-5'), 7.31 (s, 1 H, H-8), 6.61 (br s, 2 H, NH₂), 4.34 (m, 2 H, CH₂CH₂OCH₃), 3.78 (m, 2 H, CH₂CH₂OCH₃), 3.35 (s, 3 H, OCH₃). Anal. (C₁₆H₁₅ClF₂N₅O₂) C, H, N.

A solution of **72b** (0.24 g, 0.66 mmol) in THF (35 mL) was reacted with the mixed anhydride of 2,4,6-trichlorobenzoyl chloride/acrylic acid as described above. Chromatography on silica gel with gradient elution from $\text{CH}_2\text{Cl}_2/\text{EtOAc}$ (1:1) to $\text{MeOH}/\text{CH}_2\text{Cl}_2/\text{EtOAc}$ (1:4:5) gave **24** (87 mg, 32%): mp ($\text{EtOAc}/\text{Et}_2\text{O}$) 205–206 °C; ^1H NMR [$(\text{CD}_3)_2\text{SO}$] δ 10.31 (s, 1 H, CONH), 9.72 (s, 1 H, NH), 8.64 (s, 1 H, H-2), 8.35 (m, 1 H, H-2'), 7.91 (m, 1 H, H-6'), 7.73 (s, 1 H, H-8), 7.45 (dd, $J_{\text{H-F}} = 9.1$ Hz, $J = 9.1$ Hz, 1 H, H-5'), 6.66 (dd, $J = 17.0$, 10.2 Hz, 1 H, $\text{CH}=\text{CH}_2$), 6.33 (dd, $J = 17.0$, 1.9 Hz, 1 H, $\text{CH}=\text{CH}_2$), 5.83 (dd, $J = 10.2$, 1.9 Hz, 1 H, $\text{CH}=\text{CH}_2$), 4.38 (m, 2 H, $\text{CH}_2\text{CH}_2\text{OCH}_3$), 3.75 (m, 2 H, $\text{CH}_2\text{CH}_2\text{OCH}_3$), 3.35 (s, 3 H, OCH_3). Anal. ($\text{C}_{19}\text{H}_{17}\text{ClFN}_3\text{O}_3$) C, H, N.

N-[4-[N-(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]pyrido[3,2-d]pyrimidin-6-yl]-acrylamide (25). A suspension of **73** (296 mg, 0.88 mmol) in THF/DMF (4:1, 25 mL) was treated successively with K_2CO_3 (1.2 g, 8.80 mmol) and 3-bromopropan-1-ol (397 μL , 4.40 mmol). The reaction mixture was heated at reflux for 1.25 h, then diluted with water and extracted with EtOAc. The combined organic extracts were washed with brine, dried (Na_2SO_4) and evaporated. The residue was dry-loaded on silica gel and chromatographed, eluting with $\text{EtOAc}/\text{CH}_2\text{Cl}_2$ (1:1) to $\text{EtOAc}/\text{CH}_2\text{Cl}_2/\text{MeOH}$ (10:9:1), to give **4-[N-(3-chloro-4-fluorophenyl)amino]-7-(3-hydroxypropoxy)-6-(methylthio)pyrido[3,2-d]pyrimidine (74)** (215 mg, 62%): mp ($\text{MeOH}/\text{CH}_2\text{Cl}_2$) 212–214 °C; ^1H NMR [$(\text{CD}_3)_2\text{SO}$] δ 9.54 (s, 1 H, NH), 8.58 (s, 1 H, H-2), 8.27 (dd, $J_{\text{H-F}} = 6.8$ Hz, $J = 2.5$ Hz, 1 H, H-2'), 7.93 (m, 1 H, H-6'), 7.47 (partially obscured dd, $J_{\text{H-F}} = 9.2$ Hz, $J = 9.2$ Hz, 1 H, H-5'), 7.46 (partially obscured s, 1 H, H-8), 4.63 (t, $J = 5.1$ Hz, 1 H, OH), 4.33 (t, $J = 6.1$ Hz, 2 H, CH_2OAr), 3.63 (m, 2 H, CH_2OH), 2.74 (s, 3 H, SCH_3) 1.95 (quintet, $J = 6.2$ Hz, 2 H, $\text{CH}_2\text{CH}_2\text{CH}_2\text{OH}$). Anal. ($\text{C}_{17}\text{H}_{16}\text{ClFN}_3\text{O}_2\text{S} \cdot 0.5\text{H}_2\text{O}$) C, H, N.

A suspension of **74** (1.65 g, 4.18 mmol) in THF/DMF (3:1, 130 mL) was warmed to give a solution which was then cooled to 0 °C before Et_3N (12.5 mmol, 1.75 mL) and MsCl (4.60 mmol, 0.355 mL) were added. After 1 h the reaction mixture was concentrated under reduced pressure at <30 °C, then diluted with saturated NaHCO_3 and extracted with EtOAc. The combined organic extracts were washed with brine, dried (Na_2SO_4) and concentrated under reduced pressure to give the crude mesylate. This was immediately dissolved in THF (100 mL), treated with excess morpholine (4.0 mL) and heated at 50 °C for 4 days. The mixture was then concentrated, diluted with ammonia and extracted with EtOAc. The combined organic extracts were washed with brine, dried (Na_2SO_4) and evaporated. The crude product was slurried in EtOAc/hexane (1:2), filtered, and washed with Et_2O to give **4-[N-(3-chloro-4-fluorophenyl)amino]-6-(methylthio)-7-[3-(4-morpholinyl)propoxy]pyrido[3,2-d]pyrimidine (70c)** (1.46 g, 75%): mp (EtOAc) 196–198 °C; ^1H NMR [$(\text{CD}_3)_2\text{SO}$] δ 9.54 (s, 1 H, NH), 8.59 (d, $J = 1.4$ Hz, 1 H, H-2), 8.28 (m, 1 H, H-2'), 7.93 (m, 1 H, H-6'), 7.47 (m, 2 H, H-8, H-5'), 4.32 (t, $J = 6.1$ Hz, 2 H, CH_2OAr), 3.58 (t, $J = 4.6$ Hz, 4 H, morpholino methylene), 2.74 (s, 3 H, SCH_3), 2.44 (partially obscured m, 2 H, $\text{NCH}_2\text{CH}_2\text{CH}_2\text{OAr}$), 2.39 (br m, 4 H, morpholino methylene), 1.97 (quintet, $J = 6.1$ Hz, 2 H, $\text{NCH}_2\text{CH}_2\text{CH}_2\text{OAr}$). Anal. ($\text{C}_{21}\text{H}_{23}\text{ClFN}_3\text{O}_2\text{S} \cdot \text{H}_2\text{O}$) C, H, N.

A suspension of **70c** (168 mg, 0.362 mmol) in 1 N HCl (100 mL) was warmed to 40 °C to give a solution which was then cooled to 0 °C, treated with added NaIO_4 (0.398 mmol, 85 mg) and kept at 4 °C for 48 h. It was then warmed to 40 °C to dissolve precipitated starting material and cooled to 0 °C when additional NaIO_4 (40 mg) was added. After a further 24 h at 4 °C the reaction was basified by the addition of concentrated ammonia and extracted with EtOAc. The combined organic extracts were washed with brine, dried (Na_2SO_4) and evaporated. Chromatography of the residue, eluting with $\text{MeOH}/\text{CH}_2\text{Cl}_2/\text{EtOAc}$ (3:6:10), gave **4-[N-(3-chloro-4-fluorophenyl)amino]-6-(methanesulfinyl)-7-[3-(4-morpholinyl)propoxy]pyrido[3,2-d]pyrimidine (71c)** (163 mg, 94%): mp ($\text{MeOH}/\text{CH}_2\text{Cl}_2/\text{hexane}$) 160–162 °C; ^1H NMR [$(\text{CD}_3)_2\text{SO}$] δ 10.13 (s, 1 H, NH), 8.69 (d, $J = 2.0$ Hz, 1 H, H-2), 8.28 (ddd, $J_{\text{H-F}} = 6.7$

Hz, $J = 6.7$, 2.6 Hz, 1 H, H-2'), 7.93 (m, 1 H, H-6'), 7.83 (s, 1 H, H-8), 7.48 (dd, $J_{\text{H-F}} = 9.1$ Hz, $J = 9.1$ Hz, 1 H, H-5'), 4.38 (t, $J = 6.3$ Hz, 2 H, CH_2OAr), 3.58 (t, $J = 4.5$ Hz, 4 H, morpholino methylene), 3.05 (s, 3 H, $\text{S}(\text{O})\text{CH}_3$), 2.48 (partially obscured t, $J = 6.3$ Hz, 2 H, $\text{NCH}_2\text{CH}_2\text{CH}_2\text{OAr}$), 2.39 (br s, 4 H, morpholino methylene), 1.98 (quintet, $J = 6.3$ Hz, 2 H, $\text{NCH}_2\text{CH}_2\text{CH}_2\text{OAr}$). Anal. ($\text{C}_{21}\text{H}_{23}\text{ClFN}_3\text{O}_3\text{S} \cdot \text{H}_2\text{O}$) C, H, N.

A suspension of **71c** (153 mg, 0.319 mmol) in *i*-PrOH was reacted with $\text{NH}_3(\text{g})$ as above to give, after chromatography on silica gel, eluting with $\text{MeOH}/\text{CH}_2\text{Cl}_2/\text{EtOAc}$ (3:6:10), **6-amino-4-[N-(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]pyrido[3,2-d]pyrimidine (72c)** (125 mg, 91%): mp ($\text{MeOH}/\text{CH}_2\text{Cl}_2/\text{hexane}$) 192–194 °C; ^1H NMR [$(\text{CD}_3)_2\text{SO}$] δ 9.26 (s, 1 H, NH), 8.43 (s, 1 H, H-2), 8.40 (dd, $J_{\text{H-F}} = 6.9$ Hz, $J = 2.7$ Hz, 1 H, H-2'), 7.85 (m, 1 H, H-6'), 7.42 (dd, $J_{\text{H-F}} = 9.1$ Hz, $J = 9.1$ Hz, 1 H, H-5'), 7.25 (s, 1 H, H-8), 6.68 (br s, 2 H, NH₂), 4.23 (t, $J = 6.2$ Hz, 2 H, CH_2OAr), 3.59 (t, $J = 4.4$ Hz, 4 H, morpholino methylene), 2.52 (partially obscured t, $J = 6.2$ Hz, 2 H, $\text{NCH}_2\text{CH}_2\text{CH}_2\text{OAr}$), 2.40 (br s, 4 H, morpholino methylene), 1.98 (quintet, $J = 6.2$ Hz, 2 H, $\text{NCH}_2\text{CH}_2\text{CH}_2\text{OAr}$). Anal. ($\text{C}_{20}\text{H}_{22}\text{ClFN}_6\text{O}_2 \cdot 0.5\text{H}_2\text{O}$) C, H, N.

A solution of **72c** (0.39 g, 0.90 mmol) in THF (40 mL) was reacted with the mixed anhydride of 2,4,6-trichlorobenzoyl chloride and acrylic acid as described above. Chromatography on silica gel, eluting with $\text{MeOH}/\text{CH}_2\text{Cl}_2/\text{EtOAc}$ (3:6:10), gave **25** (138 mg, 31%): mp ($\text{EtOAc}/\text{Et}_2\text{O}$) 185–186 °C; ^1H NMR [$(\text{CD}_3)_2\text{SO}$] δ 10.32 (s, 1 H, CONH), 9.76 (s, 1 H, NH), 8.64 (s, 1 H, H-2), 8.37 (m, 1 H, H-2'), 7.92 (m, 1 H, H-6'), 7.68 (s, 1 H, H-8), 7.44 (dd, $J_{\text{H-F}} = 9.1$ Hz, $J = 9.1$ Hz, 1 H, H-5'), 6.63 (dd, $J = 17.2$, 10.3 Hz, 1 H, $\text{CH}=\text{CH}_2$), 6.32 (dd, $J = 17.2$, 1.7 Hz, 1 H, $\text{CH}=\text{CH}_2$), 5.83 (dd, $J = 10.3$, 1.7 Hz, 1 H, $\text{CH}=\text{CH}_2$), 4.27 (t, $J = 5.9$ Hz, 2 H, CH_2OAr), 3.57 (t, $J = 4.6$ Hz, 4 H, morpholino methylene), 2.45 (t, $J = 5.9$ Hz, 2 H, $\text{NCH}_2\text{CH}_2\text{CH}_2\text{OAr}$), 2.37 (br s, 4 H, morpholino methylene), 1.92 (quintet, $J = 5.9$ Hz, 2 H, $\text{NCH}_2\text{CH}_2\text{CH}_2\text{OAr}$). Anal. ($\text{C}_{23}\text{H}_{24}\text{ClFN}_6\text{O}_3 \cdot 0.5\text{H}_2\text{O}$) C, H, N.

N-[4-[N-(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]pyrido[3,2-d]pyrimidin-6-yl]-N-methylacrylamide (26). Excess aqueous methylamine (40%, 25 mL) was added to a solution of **71c** (0.50 g, 1.04 mmol) in DMSO (50 mL), and the mixture was heated in a sealed pressure vessel at 110 °C for 18 h, before being cooled, diluted with water and extracted with EtOAc. The combined organic extracts were washed with brine, dried (Na_2SO_4) and concentrated under reduced pressure. Chromatography of the concentrate on silica gel, eluting with $\text{CH}_2\text{Cl}_2/\text{EtOAc}$ (1:1) to $\text{MeOH}/\text{CH}_2\text{Cl}_2/\text{EtOAc}$ (2:3:5), gave **4-[N-(3-chloro-4-fluorophenyl)amino]-6-(methylamino)-7-[3-(4-morpholinyl)propoxy]pyrido[3,2-d]pyrimidine (75)** (322 mg, 69%): mp ($\text{CH}_2\text{Cl}_2/\text{Et}_2\text{O}$) 174–176 °C; ^1H NMR (CDCl_3) δ 8.58 (br s, 1 H, NHAr₂), 8.55 (s, 1 H, H-2), 8.09 (dd, $J_{\text{H-F}} = 6.5$ Hz, $J = 2.7$ Hz, 1 H, H-2'), 7.68 (m, 1 H, H-6'), 7.16 (dd, $J_{\text{H-F}} = 8.8$ Hz, $J = 8.8$ Hz, 1 H, H-5'), 7.12 (s, 1 H, H-8), 5.60 (q, $J = 4.9$ Hz, 1 H, N/CH_3), 4.23 (t, $J = 6.3$ Hz, 2 H, CH_2OAr), 3.74 (t, $J = 4.6$ Hz, 4 H, morpholino methylene), 3.18 (d, $J = 4.9$ Hz, 3 H, NCH_3), 2.55 (t, $J = 6.3$ Hz, 2 H, $\text{NCH}_2\text{CH}_2\text{CH}_2\text{OAr}$), 2.49 (br s, 4 H, morpholino methylene), 2.08 (quintet, $J = 6.3$ Hz, 2 H, $\text{NCH}_2\text{CH}_2\text{CH}_2\text{OAr}$). Anal. ($\text{C}_{21}\text{H}_{24}\text{ClFN}_6\text{O}_2$) C, H, N.

A solution of **75** (0.235 g, 0.526 mmol) in THF (40 mL) was reacted with the mixed anhydride of 2,4,6-trichlorobenzoyl chloride and acrylic acid as described above, except that the reaction was performed at 50 °C for 48 h, with additional mixed anhydride (7.5 mol equiv) in THF (20 mL) being added after 24 h. Workup as described previously (without aqueous MeOH treatment), followed by chromatography on silica gel and elution with $\text{MeOH}/\text{CH}_2\text{Cl}_2/\text{EtOAc}$ (3:6:10), gave **26** (164 mg, 62%): mp ($\text{EtOAc}/\text{Et}_2\text{O}$) 176–178 °C; ^1H NMR [$(\text{CD}_3)_2\text{SO}$] δ 10.08 (s, 1 H, CONH), 8.67 (s, 1 H, H-2), 8.33 (m, 1 H, H-2'), 7.99 (m, 1 H, H-6'), 7.80 (s, 1 H, H-8), 7.45 (dd, $J_{\text{H-F}} = 9.1$ Hz, $J = 9.1$ Hz, 1 H, H-5'), 6.17 (dd, $J = 16.6$, 2.5 Hz, 1 H, $\text{CH}=\text{CH}_2$), 6.09 (dd, $J = 10.0$, 1.6 Hz, 1 H, $\text{CH}=\text{CH}_2$), 5.58 (dd, $J = 10.0$, 2.5 Hz, 1 H, $\text{CH}=\text{CH}_2$), 4.27 (t, $J = 6.0$ Hz, 2 H, CH_2OAr), 3.57 (t, $J = 4.5$ Hz, 4 H, morpholino methylene), 3.31 (obscured s, 3 H, NCH_3), 2.38 (partially obscured t, $J =$

6.0 Hz, 2 H, $\text{NCH}_2\text{CH}_2\text{CH}_2\text{OAr}$), 2.34 (br s, 4 H, morpholino methylene), 1.89 (quintet, $J = 6.0$ Hz, 2 H, $\text{NCH}_2\text{CH}_2\text{CH}_2\text{OAr}$). Anal. ($\text{C}_{24}\text{H}_{26}\text{ClFN}_6\text{O}_3$) C, H, N.

***N*-[4-[*N*-(3-chloro-4-fluorophenyl)amino]-7-[3-(4-methyl-1-piperazinyl)propoxy]pyrido[3,2-*d*]pyrimidin-6-yl]-acrylamide (27).** Mesylation of 74 (2.69 g, 6.80 mmol) as described previously, followed by treatment of the crude mesylate with 4-methylpiperazine (3.77 mL) in THF (150 mL) at reflux for 5 days, with additional 4-methylpiperazine (5.0 mL) added after day 3, gave after workup as above, 4-[*N*-(3-chloro-4-fluorophenyl)amino]-7-[3-(4-methyl-1-piperazinyl)propoxy]-6-(methylthio)pyrido[3,2-*d*]pyrimidine (**70d**) (2.23 g, 69%): mp ($\text{EtOAc}/\text{Et}_2\text{O}$) 162–164 °C; ^1H NMR (CDCl_3) δ 8.70 (br s, 1 H, NH), 8.68 (s, 1 H, H-2), 8.10 (dd, $J_{\text{H-F}} = 6.5$ Hz, $J = 2.8$ Hz, 1 H, H-2'), 7.67 (m, 1 H, H-6'), 7.25 (s, 1 H, H-8), 7.19 (dd, $J_{\text{H-F}} = 8.8$ Hz, $J = 8.8$ Hz, 1 H, H-5'), 4.26 (t, $J = 6.2$ Hz, 2 H, CH_2OAr), 2.67 (s, 3 H, SCH_3), 2.61 (t, $J = 6.2$ Hz, 2 H, $\text{NCH}_2\text{CH}_2\text{CH}_2\text{OAr}$), 2.55–2.42 (br s, 8 H, piperazine methylenes), 2.30 (s, 3 H, NCH_3), 2.10 (quintet, $J = 6.2$ Hz, 2 H, $\text{NCH}_2\text{CH}_2\text{CH}_2\text{OAr}$). Anal. ($\text{C}_{22}\text{H}_{26}\text{ClFN}_6\text{OS}$) C, H, N.

A solution of **70d** (2.13 g, 4.47 mmol) in 1 N HCl (300 mL) was reacted with NaIO_4 as described above to give 4-[*N*-(3-chloro-4-fluorophenyl)amino]-6-(methanesulfinyl)-7-[3-(4-methyl-1-piperazinyl)propoxy]pyrido[3,2-*d*]pyrimidine (**71d**) (2.02 g, 92%): mp ($\text{CH}_2\text{Cl}_2/\text{Et}_2\text{O}$) 169–171 °C; ^1H NMR [$(\text{CD}_3)_2\text{SO}$] δ 10.19 (s, 1 H, NH), 8.70 (s, 1 H, H-2), 8.29 (m, 1 H, H-2'), 7.93 (m, 1 H, H-6'), 7.83 (s, 1 H, H-8), 7.49 (dd, $J_{\text{H-F}} = 9.0$ Hz, $J = 9.0$ Hz, 1 H, H-5'), 4.39 (t, $J = 5.8$ Hz, 2 H, CH_2OAr), 3.06 (s, 3 H, $\text{S}(\text{O})\text{CH}_3$), 3.00 (br s, 6 H, $\text{NCH}_2\text{CH}_2\text{CH}_2\text{OAr}$, piperazine methylene($\times 2$)), 2.70–2.55 (br s, 7 H, NCH_3 , piperazine methylene($\times 2$)), 2.02 (br s, 2 H, $\text{NCH}_2\text{CH}_2\text{CH}_2\text{OAr}$). Anal. ($\text{C}_{22}\text{H}_{26}\text{ClFN}_6\text{O}_2\text{S}$) C, H, N.

A suspension of **71d** (1.92 g, 3.89 mmol) in *i*-PrOH was reacted with $\text{NH}_3(\text{g})$ as described previously to give, after chromatography on alumina, eluting with $\text{CH}_2\text{Cl}_2/\text{EtOAc}$ (1:1) to $\text{MeOH}/\text{CH}_2\text{Cl}_2/\text{EtOAc}$ (1:9:10), 6-amino-4-[*N*-(3-chloro-4-fluorophenyl)amino]-7-[3-(4-methyl-1-piperazinyl)propoxy]pyrido[3,2-*d*]pyrimidine (**72d**) (1.24 g, 71%): mp ($\text{EtOAc}/\text{Et}_2\text{O}$) 190–191 °C; ^1H NMR [$(\text{CD}_3)_2\text{SO}$, 400 MHz] δ 9.22 (s, 1 H, NH), 8.43 (d, $J = 0.7$ Hz, 1 H, H-2), 8.40 (m, 1 H, H-2'), 7.84 (m, 1 H, H-6'), 7.41 (dd, $J_{\text{H-F}} = 9.1$ Hz, $J = 9.1$ Hz, 1 H, H-5'), 7.24 (s, 1 H, H-8), 6.65 (br s, 2 H, NH_2), 4.22 (t, $J = 6.1$ Hz, 2 H, CH_2OAr), 2.51 (partially obscured t, $J = 6.1$ Hz, 2 H, $\text{NCH}_2\text{CH}_2\text{CH}_2\text{OAr}$), 2.41–2.29 (br s, 8 H, piperazine methylenes), 2.14 (s, 3 H, NCH_3), 1.96 (quintet, $J = 6.1$ Hz, 2 H, $\text{NCH}_2\text{CH}_2\text{CH}_2\text{OAr}$). Anal. ($\text{C}_{21}\text{H}_{25}\text{ClFN}_6\text{O}$) C, H, N.

A solution of **72d** (0.60 g, 1.35 mmol) in THF (80 mL) was reacted with the mixed anhydride of 2,4,6-trichlorobenzoyl chloride and acrylic acid as described above. Chromatography of the crude product on silica gel, eluting with $\text{MeOH}/\text{CH}_2\text{Cl}_2/\text{EtOAc}$ (1:1:2) containing 1% Et_3N , gave **27** (223 mg, 33%): mp ($\text{EtOAc}/\text{Et}_2\text{O}$) 166–168 °C; ^1H NMR [$(\text{CD}_3)_2\text{SO}$] δ 10.33 (s, 1 H, CONH), 9.79 (s, 1 H, NH), 8.64 (s, 1 H, H-2), 8.36 (dd, $J = 6.7$ Hz, $J = 2.2$ Hz, 1 H, H-2'), 7.92 (m, 1 H, H-6'), 7.67 (s, 1 H, H-8), 7.44 (dd, $J_{\text{H-F}} = 9.2$ Hz, $J = 9.2$ Hz, 1 H, H-5'), 6.63 (dd, $J = 17.1$, 10.3 Hz, 1 H, $\text{CH}=\text{CH}_2$), 6.32 (dd, $J = 17.1$, 2.5 Hz, 1 H, $\text{CH}=\text{CH}_2$), 5.84 (dd, $J = 10.3$, 2.5 Hz, 1 H, $\text{CH}=\text{CH}_2$), 4.26 (t, $J = 6.0$ Hz, 2 H, CH_2OAr), 2.44 (t, $J = 6.0$ Hz, 2 H, $\text{NCH}_2\text{CH}_2\text{CH}_2\text{OAr}$), 2.40–2.29 (br s, 8 H, piperazine methylenes), 2.16 (s, 3 H, NCH_3), 1.91 (quintet, $J = 6.0$ Hz, 2 H, $\text{NCH}_2\text{CH}_2\text{CH}_2\text{OAr}$). Anal. ($\text{C}_{24}\text{H}_{27}\text{ClFN}_6\text{O}_2 \cdot 0.5\text{H}_2\text{O}$) C, H, N.

Aqueous Stability Study of 18 and 25. Stock solutions of the compounds in DMSO were diluted into phosphate buffers at pH 2.6, 6.67, and 10.75. The solutions were kept at 37 °C, and HPLC traces were made at time zero and at other time points out to 24 h. The peak areas of the parent drug and the amine hydrolysis product were calculated as a percent of the $t = 0$ value. The HPLC conditions were: column, Zorbax SB-C18, 4.6 mm \times 25 cm; mobile phase, 0.45 M formate buffer (ammonium formate + formic acid, pH 3.45), 80% acetonitrile, 20% MilliQ water; gradient elution, beginning aqueous/organic phase ratio 1:9, altering over 25 min to 100:0 and kept at 100:0 for another 5 min. Flow rate was 1.0 mL/min, and detection was by UV at 254 nm.

Mass Spectrometry. Solutions of compounds **18** and **25** in DMSO were added to a solution containing 25 μg of EGF receptor tyrosine kinase protein (in 20 mM Tris, 150 mM NaCl, 1 mM DTT, 1 mM EDTA) and small amounts of protease inhibitors aprotinin and leupeptin and diluted with 75 mM ammonium bicarbonate (pH 7.5). The reaction was quenched after 90 min upon addition of 5% (v/v) acetic acid, and the protein was purified and concentrated by centrifugal filtration (Microcon-10, 10-kDa cutoff filter, Amicon, Inc., Beverly, MA). The molecular weight of the protein–drug complex in a denaturing solution (80% CH_3CN , pH 2.5) was determined by ESI-MS (MAT 900Q mass spectrometer, Finnigan MAT, Bremen, Germany) equipped with a low-flow micro-ESI source operating at 150 nL/min. A portion of drug-bound protein was reduced, alkylated, and digested with trypsin. Peptide sequence analysis was performed by LC–ESI-MS/MS with a quadrupole ion trap mass spectrometer (Finnigan LCQ, Finnigan Corp., San Jose, CA) interfaced with a Michrom BioResources Magic 2002 HPLC (Auburn, CA). Peptides were eluted from the 0.3 \times 15-mm Vydac C18 column directly into the mass spectrometer with a linear gradient of CH_3CN at 5 $\mu\text{L}/\text{min}$ as follows: 5% solvent B to 95% solvent B over 10 min (where A = 0.05% TFA/2% CH_3CN and B = 0.045% TFA/90% CH_3CN).

Cell Culture. A431 human epidermoid carcinoma cells were obtained from the American Type Culture Collection, Rockville, MD, and maintained as monolayers in α MEM (Dulbecco's modified eagle medium)/F12, 50:50 (Gibco/BRL) containing 10% fetal bovine serum. For growth inhibition assays, dilutions of the designated compound in 10 mL were placed in 24-well Linbro plates (1.7 \times 1.6 cm, flat bottom) followed by the addition of cells (2×10^4) in 2 mL of media. The plates were incubated for 72 h at 37 °C in a humidified atmosphere containing 5% CO_2 in air. Cell growth was determined by cell count with a Coulter model AM electronic cell counter (Coulter Electronics, Inc., Hialeah, FL).

Tyrosine Kinase Assays. EGFR tyrosine kinase was purified as described previously.²¹ Enzyme assays for IC₅₀(app) determinations were performed in 96-well filter plates (Millipore MADVN6550, Millipore, Bedford, MA). The total volume was 0.1 mL containing 20 mM Hepes, pH 7.4, 50 mM sodium vanadate, 40 mM magnesium chloride, 10 μM adenosine triphosphate (ATP) containing 0.5 mCi of [^{32}P]ATP, 20 mg of polyglutamic acid/tyrosine (Sigma Chemical Co., St. Louis, MO), 10 ng of EGFR tyrosine kinase, and appropriate dilutions of inhibitor. All components except the ATP were added to the well and the plate was incubated with shaking for 10 min at 25 °C. The reaction was started by adding [^{32}P]ATP, and the plate was incubated at 25 °C for 10 min. The reaction was terminated by addition of 0.1 mL of 20% trichloroacetic acid (TCA). The plate was kept at 4 °C for at least 15 min to allow the substrate to precipitate. The wells were then washed five times with 0.2 mL of 10% TCA and ^{32}P incorporation determined with a Wallac beta plate counter (Wallac, Inc., Gaithersburg, PA).

Irreversibility Test Protocol. A431 human epidermoid carcinoma cells were grown in 6-well plates to about 80% confluency and then incubated in serum-free media for 18 h. Duplicate sets of cells were treated with 2 mM of designated compound to be tested as an irreversible inhibitor for 2 h. One set of cells was then stimulated with 100 ng/mL EGF for 5 min and extracts made as described under the Western blotting procedure. The other set of cells was washed free of the compound with warmed serum-free media, incubated for 2 h, washed again, incubated another 2 h, washed again, and then incubated a further 4 h. This set of cells was then stimulated with EGF and extracts were made similar to the first set of cells.

Western Blotting Procedure. Extracts were made by lysing cells in 0.2 mL of boiling Laemmli buffer (2% sodium dodecyl sulfate, 5% β -mercaptoethanol, 10% glycerol, and 50 mM tris(hydroxymethyl)aminomethane (Tris), pH 6.8), and the lysates were heated to 100 °C for 5 min. Proteins in the lysate were separated by polyacrylamide gel electrophoresis and

electrophoretically transferred to nitrocellulose. The membrane was washed once in 10 mM Tris, pH 7.2, 150 mM NaCl, 0.01% azide (TNA), and blocked overnight in TNA containing 5% bovine serum albumin and 1% ovalbumin. The membrane was blotted for 2 h with antiphosphotyrosine antibody (UBI, 1 mg/mL in blocking buffer) and then washed twice in TNA, once in TNA containing 0.05% Tween-20 detergent and 0.05% nonidet P-40 detergent, and twice in TNA. The membranes were then incubated for 2 h in blocking buffer containing 0.1 mCi/mL [¹²⁵I]protein A and then washed again as above. After the blots were dry, they were loaded into a film cassette and exposed to X-AR X-ray film (Eastman Kodak Co., Rochester, NY) for 1–7 days. Band intensities were determined with a Molecular Dynamics laser densitometer.

Caco-2 Cell Permeability. The absorptive and secretory transport of compounds **18** and **25** were carried out in Caco-2 cells.²⁴ Apical-to-basolateral (A→B) and basolateral-to-apical (B→A) experiments were performed in side-by-side diffusion apparatus with 25 μ M of drug. [¹⁴C]Mannitol was used to monitor cell integrity and [³H]metoprolol, which is 90–95% absorbed in human,^{30,31} was used as a reference compound. Cells were at passage 35 or 21, 23 or 25 days post-seeding, with an average TEER measurement of 430–508. The incubation solutions were prepared in Hank's balanced salt solution (HBSS) with 2% ethanol and 2% DMSO; pH was 6.5 and 7.4, respectively, in apical and basolateral compartments. Bidirectional transport experiments of [³H]vinblastine were performed simultaneously for confirmation of P-gp activity.^{25,26} Drug concentrations were monitored using an LC-MS/MS method; reference compounds were measured using scintillation counting.

The effect of **18** and **25** on P-glycoprotein transport was carried out using Caco-2 cells of passage 21, 21 days post-seeding with an average TEER measurement of 484. Apical-to-basolateral (A→B) and basolateral-to-apical (B→A) control experiments were performed in side-by-side diffusion apparatus with [³H]vinblastine in the donor compartment. The compounds (25 μ M) were added to both apical and basolateral compartments in B→A experiments to examine its inhibitory effects on [³H]vinblastine efflux. Cyclosporin (10 μ M) was also used as a positive control inhibitor,^{27,28} and [¹⁴C]mannitol was used to monitor cell integrity. The incubation solutions were prepared in Hank's balanced salt solution (HBSS) buffer (pH 6.5 apical, pH 7.4 basolateral) with 2% EtOH and 2% DMSO as cosolvents. [¹⁴C]Mannitol permeability values indicated that the cell monolayers remained viable throughout these studies.

In Vivo Chemotherapy. Immune-deficient mice were housed in microisolator cages within a barrier facility on a 12-h light/dark cycle and received food and water ad libitum. Animal housing was in accord with AAALAC guidelines. All experimental protocols involving animals were approved by the institutional animal care and use committee. The A431 epidermoid carcinoma was maintained by serial passage in nude mice (NCR nu/nu). Nude mice were also used as tumor host for anticancer agent evaluations against this tumor model. In each experiment, test mice weighing 18–22 g were randomized and implanted with tumor fragments in the region of the right axilla on day 0. Animals were treated with test compounds on the basis of average cage weight (6 mice/dose group) initiated when tumors reached approximately 100–150 mg in mass and continued for the period indicated in Table 3. Whenever possible test compounds were evaluated over a range of dose levels ranging from toxic to ineffective.

The doses reported in Table 3 are the maximum doses that could be administered without exceeding the LD₅₀, unless otherwise indicated. This maximum tolerated dose (MTD) allows comparisons to be made among the tested compounds at an equitoxic dose level. Derivatives **8** and **18** were administered as solutions of the isethionate salt generated in situ by the addition of 1.5 equiv of aqueous isethionic acid followed by dilution to dosing volume with distilled water (final pH 4). Compound **25** was dissolved directly in 50 mM sodium lactate buffer, pH 4. Compound dosing solutions were prepared for 5 days at a time. Host body weight change data are reported as

the maximum treatment-related weight loss in these studies. Calculations of tumor growth inhibition (% T/C) and tumor growth delay (T–C) were performed as described previously.^{32–35}

Acknowledgment. This work was partially supported by the Auckland Division of the Cancer Society of New Zealand. The authors thank Karin Tan for HPLC studies.

References

- (1) Kersemaekers, A. M. F.; Fleuren, G. J.; Kenter, E. G.; Van den Broek, L. J. C. M.; Uljee, S. M.; Hermans, J.; Van de Vijver, M. J. Oncogene alterations in carcinomas of the uterine cervix: Overexpression of the epidermal growth factor receptor is associated with poor prognosis. *Clin. Cancer Res.* **1999**, *5*, 577–586.
- (2) Maurizi, M.; Almadori, G.; Ferrandina, G.; Distefano, M.; Romanini, M. E.; Cadoni, G.; Benedetti-Panici, P.; Paludetti, G.; Scambia, G.; Mancuso, S. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. *Br. J. Cancer* **1996**, *74*, 1253–1257.
- (3) Kihls, W. D.; Fry, D. W.; Kraker, A. J. Inhibitors of tyrosine kinase. *Curr. Opin. Oncol.* **1997**, *9*, 562–568.
- (4) Voldborg, B. R.; Damstrup, L.; Spang-Thomsen, M.; Poulsen, H. S. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. *Ann. Oncol.* **1997**, *8*, 1197–1206.
- (5) Kelloff, G. J.; Fay, J. R.; Steele, V. E.; Lubet, R. A.; Boone, C. W.; Crowell, J. A.; Sigman, C. C. Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. *Cancer Epidemiol. Biomarkers Prevention* **1996**, *5*, 657–666.
- (6) Thompson, A. M.; Bridges, A. J.; Fry, D. W.; Kraker, A. J.; Denny, W. A. Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]pyrido[4,3-d]pyrimidines: a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. *J. Med. Chem.* **1995**, *38*, 3780–3788.
- (7) Bridges, A. J.; Zhou, H.; Cody, D. R.; Rewcastle, G. W.; McMichael, A.; Showalter, H. D. H.; Fry, D. W.; Kraker, A. J.; Denny, W. A. Tyrosine kinase inhibitors. 8. An unusually steep structure–activity relationship for analogues of 4-(3-bromo-anilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. *J. Med. Chem.* **1996**, *39*, 267–276.
- (8) Wakeling, A. E.; Barker, A. J.; Davies, D. H.; Brown, D. S.; Green, L. R.; Cartledge, S. A.; Woodburn, J. R. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. *Breast Cancer Res. Treat.* **1996**, *38*, 67–73.
- (9) Rewcastle, G. W.; Palmer, B. D.; Thompson, A. M.; Bridges, A. J.; Cody, D. R.; Zhou, H.; Fry, D. W.; McMichael, A.; Denny, W. A. Tyrosine Kinase Inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor. *J. Med. Chem.* **1996**, *39*, 1823–1835.
- (10) Fry, D. W.; Nelson, J. M.; Slitak, V.; Keller, P. R.; Rewcastle, G. W.; Denny, W. A.; Zhou, H.; Bridges, A. J. Biochemical and antiproliferative properties of 4-[ar(alkyl)amino]-pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor. *Biochem. Pharmacol.* **1997**, *54*, 877–887.
- (11) Woodburn, J. R.; Barker, A. J.; Gibson, K. H.; Ashton, S. E.; Wakeling, A. E.; Curry, B. J.; Scarlett, L.; Henthorn, L. R. ZD 1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical trial development. *Proc. Am. Assoc. Cancer Res.* **1997**, *38*, 633 (Abstract 4251).
- (12) Moyer, J. D.; Barbacci, E. G.; Iwata, K. K.; Arnold, L.; Boman, B.; Cunningham, A.; DiOrto, C.; Doti, J.; Morin, M. J.; Moyer, M. P.; Neveu, M.; Pollack, V. A.; Pustilnik, L. R.; Reynolds, M. M.; Sloane, D.; Theleman, A.; Miller, P. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. *Cancer Res.* **1997**, *57*, 4838–4848.
- (13) Fry, D. W.; Bridges, A. J.; Denny, W. A.; Doherty, A.; Gries, K. D.; Hicks, J. L.; Hook, K. E.; Keller, P. R.; Leopold, W. R.; Loo, J. A.; McNamara, D. J.; Nelson, J. M.; Sherwood, V.; Smaill, J. B.; Trumpf-Kallmeyer, S.; Dobrusin, E. M. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. *Proc. Natl. Acad. Sci. U.S.A.* **1998**, *95*, 12022–12027.
- (14) Smaill, J. B.; Palmer, B. D.; Rewcastle, G. W.; Denny, W. A.; McNamara, D. J.; Dobrusin, E. M.; Bridges, A. J.; Zhou, H.; Showalter, H. D. H.; Winters, R. T.; Leopold, W. R.; Fry, D. W.; Nelson, J. M.; Slitak, V.; Elliot, W. L.; Roberts, B. J.; Vincent,

- P. W.; Patmore, S. J. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[*d*]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor. *J. Med. Chem.* **1999**, *42*, 1803–1815.
- (15) Sherwood, V.; Bridges, A. J.; Denny, W. A.; Rewcastle, G. W.; Smaill, J. B.; Fry, D. W. Selective inhibition of heregulin-dependent tyrosine phosphorylation and cellular signaling through erbB2, erbB3 and erbB4 by PD 158780 and a new irreversible inhibitor, PD 183805. *Proc. Am. Assoc. Cancer Res.* **1999**, *40*, 723 (Abstract 4778).
- (16) Gogolimska, B.; Gruda, I. Synthesis of bromonitrobenzyl bromides. *Acta Polon. Pharm.* **1963**, *20*, 345–346; *Chem. Abstr.* **1963**, *62*, 463.
- (17) Morley, J. S.; Simpson, J. C. E. The chemistry of simple heterocyclic systems. Part 1. Reactions of 6- and 7-nitro-4-hydroxyquinazoline and their derivatives. *J. Chem. Soc.* **1948**, 360–366.
- (18) Barraclough, P.; Black, J. W.; Cambridge, D.; Collard, D.; Firmin, D.; Gerskowitch, V. P.; Glen, R. C.; Giles, H.; Hill, A. P.; Hull, R. A. D.; Iyer, R.; King, W. R.; Kneen, C. O.; Lindon, J. C.; Nobbs, M. S.; Randall, P.; Shah, G. P.; Smith, S.; Vine, S. J.; Whiting, M. V.; Williams, J. M. Inotropic "A" ring substituted sulmazole and isomazole analogues. *J. Med. Chem.* **1990**, *33*, 2231–2239.
- (19) Roth, C. A.; Tai, J. J. A new synthesis of aryl substituted quinazolin-4(1*H*)-ones. *J. Heterocycl. Chem.* **1996**, *33*, 2051–2053.
- (20) Palmer, B. D.; Trumpp-Kallmeyer, S.; Fry, D. W.; Nelson, J. M.; Showalter, H. D. H.; Denny, W. A. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding. *J. Med. Chem.* **1997**, *40*, 1519–1529.
- (21) Thompson, A. M.; Murray, D. K.; Elliott, W. L.; Fry, D. W.; Nelson, J. A.; Showalter, H. D. H.; Roberts, B. J.; Vincent, P. W.; Denny, W. A. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromo-phenyl)amino]-pyrido[4,3-*d*]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. *J. Med. Chem.* **1997**, *40*, 3915–3925.
- (22) Trinks, U.; Buchdunger, E.; Furet, P.; Kump, W.; Mett, H.; Meyer, T.; Muller, M.; Regenass, U.; Rihs, G.; Lydon, N.; Traxler, P. Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase. *J. Med. Chem.* **1994**, *37*, 1015–1027.
- (23) Fenn, J. B.; Mann, M.; Meng, C. K.; Wong, S. F.; Whitehouse, C. M. Electrospray ionization for mass spectrometry of large biomolecules. *Science* **1989**, *246*, 64–71.
- (24) Stewart, B. H.; Chan, O. H.; Lu, R. H.; Reyner, E. L.; Schmid, H. L.; Hamilton, H. W.; Steinbaugh, B. A.; Taylor, M. D. Comparison of intestinal permeabilities determined in multiple in vitro and in situ models: relationship to absorption in humans. *Pharm. Res.* **1995**, *12*, 693–699.
- (25) Scala, S.; Akhmed, N.; Rao, U. S.; Paull, K.; Lan, L. B.; Dickstein, B.; Lee, J. S.; Elgemele, G. H.; Stein, W. D.; Bates, S. E. P-Glycoprotein substrates and antagonists cluster into two distinct groups. *Mol. Pharmacol.* **1997**, *51*, 1024–1033.
- (26) Horio, M.; Lovelace, E.; Pastan, I.; Gottesman, M. M. Agents which reverse multidrug-resistance are inhibitors of [3H]vinblastine transport by isolated vesicles. *Biochim. Biophys. Acta* **1991**, *1061*, 106–111.
- (27) Zacherl, J.; Hamilton, G.; Thalhammer, T.; Riegler, M.; Cosentini, E. P.; Ellinger, A.; Bischof, G.; Schweitzer, M.; Teleky, B.; Koperna, T.; Wenzl, E. Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil, cyclosporine A and SDZ PSC 833 in dependence on extracellular pH. *Cancer Chemother. Pharmacol.* **1994**, *34*, 125–132.
- (28) Ford, J. M.; Hait, W. M. Pharmacology of drugs that alter multidrug resistance in cancer. *Pharmacol. Rev.* **1990**, *42*, 155–199.
- (29) Rewcastle, G. W.; Palmer, B. D.; Bridges, A. J.; Showalter, H. D. H.; Sun, L.; Nelson, J.; McMichael, A.; Kraker, A. J.; Fry, D. W.; Denny, W. A. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. *J. Med. Chem.* **1996**, *39*, 918–928.
- (30) Meier, J. Pharmacokinetic comparison of pindolol with other beta-adrenoceptor-blocking agents. *Am. Heart J.* **1982**, *104*, 364–373.
- (31) Fagerholm, U.; Johansson, M.; Lennernas, H. Comparison between permeability coefficients in rat and human jejunum. *Pharm. Res.* **1996**, *13*, 1336–1342.
- (32) Schabel, F. M., Jr.; Griswold, D. P., Jr.; Laster, W. R., Jr.; Corbett, T. H.; Lloyd, H. H. Quantitative evaluation of anticancer agent activity in experimental animals. *Pharmacol. Ther.* **1977**, *1*, 411–435.
- (33) Leopold, W. R.; Nelson, J. M.; Plowman, J.; Jackson, R. C. Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors. *Cancer Res.* **1985**, *45*, 5532–5539.
- (34) Elliott, W. L.; Howard, C. T.; Dykes, D. J.; Leopold, W. R. Sequence and schedule-dependent synergy of trimetrexate in combination with 5-fluorouracil in vitro and in mice. *Cancer Res.* **1989**, *49*, 5586–5590.
- (35) Elliott, W. L.; Roberts, B. J.; Howard, C. T.; Leopold, W. R. Chemotherapy with [SP-4-3-(*R*)]-[1,1-cyclobutanedicarboxylato-(2-)](2-methyl-1,4-butanediamine-*N,N*)platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo. *Cancer Res.* **1994**, *54*, 4412–4418.

JM990482T

Organization **TC1600** Bidg/Room **REMSEN**

United States Patent and Trademark Office

P.O. Box 1450

Alexandria, VA 22313-1450

If Undeliverable Return in Ten Days

OFFICIAL BUSINESS

PENALTY FOR PRIVATE USE, \$300

AN EQUAL OPPORTUNITY EMPLOYER

